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SUMMARY
A major objective in transplant research is to achieve tolerance to 
alloantigen by modifying the host immune system at the time of grafting, thereby 
avoiding the need for exogenous immunosuppression. Much recent interest has 
focused on the cytokines produced by immunoregulatory cells, to determine 
whether manipulating secretion of such molecules may prove beneficial for 
allograft survival. These cytokines are a diverse group of proteins, produced 
during the effector phase of both the innate and the specific immune responses 
and they serve to mediate and regulate the immune response.
T helper cells are critical to the adaptive immune response and can be 
divided into functionally distinct subsets according to the repertoire of cytokines 
which they produce, Thl cells producing Interleukin-2 (IL-2), Interferon-y (IFN-y) 
and Tumour Necrosis factor-{3 (TNF-P) and Th2 cells producing IL-4, IL-5 and 
IL-10, with ThO cells being an undifferentiated common precursor. Thl cells are 
responsible for cell-mediated immunity as they stimulate cytotoxic T cells and 
NK cells, activate macrophages and control antibody-dependent cell cytotoxicity. 
In contrast, Th2 cells provide optimal help for humoral immune responses by 
inducing production of IgE, IgG 1 and enhancing mucosal immunity.
Allograft rejection is primarily attributable to cell-mediated immunity and 
is associated with an increase in Thl type cytokines. Immunological tolerance to 
allografts is usually associated with a decrease in Thl cytokines and, in some, but 
not all situations, a preservation or increase in Th2 cytokines. Consequently,
induction of tolerance to allografts may be associated with the preferential 
activation of Th2 cells.
An important factor which determines the polarisation of undifferentiated 
ThO cells into Thl or Th2 cells is the cytokine environment present at the time of 
antigen presentation to the ThO cell. IL-12 is a potent cytokine for induction of 
Thl responses, while IL-4 promotes Tli2 responses. These two cytokines have 
antagonistic effects on each other. IL-12 is, therefore, a key immunoregulatory 
cytokine: it induces ThO cells to differentiate into Thl cells; it promotes cytotoxic 
lymphocyte activity; it induces production of other Thl cytokines such as IFN-y, 
and it inhibits the generation of Th2 responses.
Antagonism of endogenous IL-12 can switch various pathological 
processes from a Thl to a Th2 mediated disease and this can result in dramatic 
changes in the disease process (e.g. protozoan infections, acute allergic 
encephalomyelitis, experimental colitis). IL-12 is, therefore, an attractive target 
molecule in allograft rejection. By inhibiting IL-12, it may be possible to prevent 
the generation of the characteristic Thl response to an allograft and, instead, 
induce a Tli2 response. This, in turn, may lead to prolonged survival of the graft.
This aim of this study was to examine the effect of neutralising 
endogenous IL-12 on skin allograft survival in a mouse experimental model. The 
immune response following treatment was investigated to determine whether 
anti-IL-12 antibody could switch a Thl to a Th2 response and whether this was 
associated with prolonged graft survival.
C57B1/6 and DBA/2 mice were grafted with tail skin from semi- 
allogeneic (C57B1/6 X DBA/2) Fi (BDFi) donors. Skin graft survival was 
compared between untreated mice and those treated with a neutralising goat anti­
mouse IL-12 polyclonal antibody. In addition, mice were pre-treated with donor 
specific transfusion in the form of BDFi spleen cells injected intravenously prior 
to grafting, or with a combination of both anti-IL -12 antibody and donor cell pre­
treatment.
Skin graft survival was not prolonged in animals which had been treated 
with anti-IL-12 antibody or donor cell injection alone compared to umnodified 
controls. Allograft survival was, however, significantly prolonged in animals pre­
treated with both anti-IL-12 antibody plus donor cell injection. Interestingly, 
when a fully allogeneic mismatch was used, this combined treatment did not 
prolong graft survival.
The immunological processes involved with the rejection response were 
investigated. The spleens of treated and untreated mice were removed at various 
time points after grafting and single cell suspensions prepared and maintained in 
vitro. When re-stimulated with irradiated BDFi cells in a MLR, cells from 
unmodified C57B1/6 graft recipients proliferated well. However, where animals 
had been pre-treated with donor cells, either with or without anti-IL-12 antibody, 
proliferation was markedly reduced, although such a reduction was not associated 
with prolonged graft survival. Pre-treatment with anti-IL-12 antibody alone did 
not reduce proliferation in vitro. Supernatants from cultures of spleen cells from 
treated animals re-stimulated with donor-specific antigen were analysed for their 
cytokine content by ELISA. Unmodified graft rejection was associated with
increased production of the Thl cytokines, IL-2 and IFN-y. Treatment with donor 
cells prior to grafting abolished this Thl response in vitro, with cells producing 
little Thl or Th2 cytokines, although grafts were still rejected at the normal time. 
Treatment with anti-IL-12 antibody alone induced cells to produce less IFN-y in 
vitro and also slightly increased production of the Th2 cytokines, IL-5 and IL-10, 
although this did not alter allograft rejection. Pre-treatment with both anti-IL-12 
antibody and donor cells abolished a Thl response and significantly increased 
Th2 cytokine production and this was associated with prolonged allograft 
survival. In this model, therefore, prolonged skin graft survival appeared to be 
associated with an increased Th-2 response and a down-regulated Th-1 response 
when cells from treated animals were re-stimulated in vitro.
Specific cytotoxicity, as measured by CTL activity in spleen cell 
preparations was not reduced by neutralising endogenous IL-12, but NK cell 
activity was reduced. NK cells are responsible for the elimination of injected 
foreign cells, and persistence of such injected cells within the host has been 
shown by others to prolong allograft survival. However, using FACS analysis, it 
was not possible to demonstrate that reduced NK cell activity directly led to 
increased survival of injected BDFi cells in treated animals in this model.
Thus inhibition of endogenous IL-12, together with donor cell pre­
treatment, prolonged skin graft survival and this was associated with an up- 
regulated Th2 response and a down-regulated Thl response. This indicates that 
effecting a switch to a Th2 response ean prove beneficial for allograft survival.
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CHAPTER 1
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1.1 The Immune System
The immune system of man and other mammals has evolved into a 
sophisticated and closely regulated series of mechanisms which serve to protect 
the individual against the threat of infection and colonisation. It has the ability to 
recognise foreign antigens, differentiate them from host or self constituents and to 
institute effector mechanisms to eliminate or destroy such antigens. In addition, it 
retains an immunological memory in order that, on re-exposure to such antigens, 
recognition and elimination proceed rapidly.
The mammalian immune system has conventionally been divided into 2 
parts, the innate and the adaptive systems. It must be appreciated, however, that 
functionally no division exists, with both systems working in a co-ordinated 
fashion to provide immune responses to any antigen (reviewed in Austyn and 
Wood, 1993).
1.1.1 The Innate Immune System
The innate immune system includes all non-specific resistance 
mechanisms and can recognise and eliminate antigen in a variety of ways. A 
fundamental feature of this arm of the immune response is the speed with which 
such recognition and effector mechanisms can be instituted. The innate system 
does not, however, possess specificity of recognition or elimination and the 
mechanisms of destruction usually work indiscriminately. This involves the 
inflammatory response which starts with activation of both cellular and humoral 
components by antigen (Austyn and Wood, 1993).
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Immune responses are produced primarily by leucocytes, of which there 
are several different types. One important group is the phagocytic cells such as 
monocytes, macrophages and polymorphonuclear neutrophils. They bind to 
antigen, internalise it and destroy it, using primarily non-specific recognition 
systems and thus mediate the innate response.
A wide variety of soluble molecules are also involved in the development 
of immune responses. The complement system is a group of serum proteins which 
interact with one another in a cascade which can opsonize bacteria, act as 
chemoattractants and cause damage to cell membranes leading to cell lysis. 
Cytokines (dealt with more fully below) form a large group of molecules involved 
in signalling between cells during an immune response. These components all 
serve to co-ordinate and direct the innate arm of the immune response, but can 
also interact with components of the adaptive response.
1.1.2 The Adaptive Immune System
The adaptive immune response is highly specific for any particular 
antigen and this response improves with each successive encounter with that 
antigen. Lymphocytes are the cell type central to the adaptive response since they 
specifically recognise individual pathogens either inside host cells or in tissue 
fluids or blood (Austyn and Wood, 1993). Lymphocytes can be characterised in 
many ways, but essentially fall into 2 groups, T and B lymphocytes. T cells 
recognise specific antigens via a specific receptor, the T cell antigen receptor 
(TCR). However, for this to occur, antigen must be presented in association with 
specific cell surface molecules, termed major histocompatibility antigens,
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expressed on host cell surfaces (eg Shoskes and Wood, 1994, Larsen and Pearson, 
1997). T cells have also been characterised by the surface molecules which they 
express: CD4’*' T cells express the CD4 molecule and are often, but not 
exclusively, T helper (Th) cells while CDS’*" cells express the CD8 molecule and 
are usually cytotoxic T (Tc) cells (Zamoyska, 1998).
During an immune response there is a considerable degree of interaction 
between lymphocytes and phagocytes. For example, phagocytic cells, such as 
dendritic cells, will take up antigen, process it and present it on their surface in a 
form which can be recognised by T cells. Such antigen presenting cells (APCs) 
play a vital role in presenting antigenic material to the adaptive immune system 
(eg VanBuskirk et al, 1997, Grewal and Flavell,1998). Some cells such as 
dendritic cells and Langerlians cells are “professional” APCs, whilst other cell 
types such as endothelial, epithelial and B cells can act as APCs when stimulated 
with cytokines. T cells also release soluble mediators in the form of various 
cytokines which can activate phagocytic cells and also influence other T and B 
cells. Thus many immune responses are made up of a variety of innate and 
adaptive components.
1.2 Cytokines
The cytokines are families of molecules such as interleukins, 
lymphokines, growth factors, interferons and chemokines which act as mediators 
of short range signals between cells (Sanchez-Cuenca et al, 1999). These signals 
are transduced via specific receptors on target cells (Taga and Kishimoto, 1990). 
They produce a wide array of biological effects which frequently overlap with the
20
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effects of other cytokines, giving redundancy within these systems (Paul, 1989). In 
vivo, the effects of most cytokines are usually restricted to those cells in the 
immediate vicinity of release. Cytokine secretion is itself a brief, self-limited 
event as these molecules are not stored as preformed molecules, their synthesis 
being initiated by transient gene transcription. In addition, individual cytokines 
often influence the synthesis of other cytokines, leading to regulatory positive or 
negative feedback mechanisms and so they can amplify or antagonise each others 
actions (Gately et al, 1998).
The complete characterisation of many of the cytokines has made it
possible to classify them according to their structure, biological activity and the
structure of their specific receptor (Bazan, 1990, a). Interleukins were defined as
the molecules which transmit signals between leulcocytes and, structurally, they
can be divided into 2 groups: those with 4-a-helical short chain structures or those
with [3-sheets. Most of the cytokines with a 4-a-helical structure bind to a receptor
with a haemopoietin ligand binding domain (Bazan, 1990, b). The receptors for
.these cytokines are heterodimers with a unique, ligand binding chain and a
common intracellular chain beaiing domains necessary for signal transduction. 
Thus IL-2, IL-3, IL-4, IL-5, IL-7, lL-9, IL-13 and IL-15 all share a similar 
structure in the form of a 4-a-helical short chain while IL -la  and IL-1(3 have a (3
sheet structure. IL-2, IL-4, IL-7, IL-9 and IL-13 receptors all have a component
. .specific for that cytokine, but this is linlced to a common intracellular signalling 
component in the form of a y chain. These receptors are all part of the 
haemopoeitin receptor family. Similarly, the receptors for IL-3 and IL-5 are also 
derived from the haemopoietin receptor family but share a common (3 chain, while
I
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IL-6 has a gp 130 chain in its receptor which is essential for signal transduction 
(Taga and Kishimoto, 1997). The interferons (ÏFN) bind to a IFN receptor domain. 
These common structures suggest that cytokines and their receptors may have 
diversified together in the evolution of increasingly specialized effector functions 
and the shai'ed use of signal transducers in the multichain receptor complexes has 
been used to explain the frmctional redundancy of many of the cytokines (Taga 
and Kishimoto, 1997). Individual cytokines are produced by different cell types 
and can have more than one cell type as a target. This is summarised in Figure 1.1. 
The functions of the cytokines relevant to this work are discussed later.
1.3 Transplantation
Transplantation of allogeneic organs from one individual to another has 
become increasingly common in recent years as improvements in surgical 
technique and post-operative care have been made. The major limitation in this 
field is, however, the problem of graft rejection. The transplantation of allogeneic 
tissue leads to a vigorous immune response as the host immune system recognises 
the grafted tissue as foreign and attempts to destroy it (Wood and Morris, 1995). 
Despite advances in immunosuppressive therapy, allograft rejection remains a 
significant problem, as does long term treatment with immunosuppressive agents 
which are associated with significant side-effects. Much attention has, therefore, 
been directed at looking for ways in which to modulate the immune system at the 
time of transplantation to prevent allograft rejection and so avoid the need for 
ongoing immunosuppression. In order to examine this, one must first have some
22
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understanding of how the host immune system recognises and responds to the 
allogeneic graft.
1.4 Allograft Rejection
The immunological destruction of an allogeneic graft is a complex
process and involves different effector mechanisms. In the clinical setting, 3 types
.of graft rejection are recognised. Hyperacute rejection is mediated by preformed
.antibody which destroys the blood supply of vascularised organs (Williams et al, 
1968). Binding of preformed antibody to donor antigen on endothelium initiates a 
cascade of events leading to vascular thrombosis. Complement fixation and
activation of bradykinins and other vasoactive substances are involved in the
destructive process (Jooste et al, 1981, VanBuskirk et al, 1997) and this occurs
within minutes of restoring the circulation to the grafted organ. In a clinical
setting, however, hyperacute rejection can usually be avoided by the use of cross-
. .match testing prior to grafting to indicate whether a recipient will reject a 
particular graft in the immediate post-operative period (Scornik et al, 1992, 
Chapman et al, 1986).
Rejection episodes occurring in the first few weeks after grafting are 
termed acute rejection and this is usually attributed to cell mediated immunity, 
provoking a delayed type hypersensitivity (DTH) reaction (Hall, 1991), although 
alio antibody may also be involved (Costa et al, 1997, Tweedle et al, 1996). Acute 
rejection is characterised by the presence of donor-reactive T cells and such cells 
are required for rejection to proceed (Rosenberg and Singer, 1992). The essential 
role of T cells in this process has been demonstrated by adoptive transfer studies
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in T cell-deficient graft recipients. Thus athymic nude mice will accept tissue 
grafts from allogeneic sources (Manning et al, 1973), but rejection can be brought 
about by reconstituting such mice with purified syngeneic T cells (Rosenberg et al, 
1986, Bolton et al, 1989). It is thought that T cells recognise alloantigen on APCs, 
and this leads to T cell activation. Cytokine production and other cellular 
interactions take place as Th cells recruit and activate other cells, including Tc and 
macrophages, and this leads to tissue destruction (VanBuskirk et al, 1997).
Most organs which undergo acute rejection do so within the first tlnee 
months after transplantation. However, some organs are lost after this period and 
this has been termed chionic rejection. In the clinic, acute rejection can often be 
controlled pharmacologically and so chronic rejection has become a significant 
problem, occurring in around half of all transplant patients. Chronic rejection is 
characterised by the slow development of interstitial fibrosis and neointimal 
proliferation within larger blood vessels and this process is unresponsive to 
current immunosuppressive therapies (Orosz et al, 1997, Hayry et al, 1993). In the 
past, acute and chronic rejection have been viewed as separate entities, but more 
recent evidence has shown that the number of acute rejection episodes has a strong 
influence on the development of chronic rejection (Matas et al, 1994), suggesting 
that the 2 processes may be comiected. Chronic rejection results from the 
progressive development of sclerosis in larger arteries in the graft, which 
decreases blood flow, inducing tissue ischaemia and fibrosis, leading to graft 
failure. T cells have been shown to contribute significantly to neointimal 
proliferation within the graft vessels (Cramer and Shirwan, 1998). In addition, 
however, circulating alloantibody is present in chionic rejection and can itself
24
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cause neointimal proliferation (Russell et al, 1994, Cramer and Shirwan, 1998). 
Thus clironic rejection is a complex phenomenon where both cell-mediated and 
humoral mechanisms play a role but, as yet, a full understanding of their
significance remains elusive.
1.4.1 Cell Types Involved in Rejection
Despite widespread agreement that T cells play a central role in allograft 
rejection (Bolton et al, 1989, Rosenberg and Singer, 1992), controversy remains 
regarding the actual mechanisms involved. While T cells invade grafts, other cell 
types are also to be found within the graft during rejection.
Progressive infiltration of the graft by host mononuelear cells is 
characteristic of acute rejection of allogeneic tissues (Tilney et al, 1994). Soon 
after the circulation to the allograft is restored there is invasion by host 
lymphocytes, initially into the perivascular areas and then throughout the graft. 
Over the following days the inflammatory cell infiltrate increases, with a large 
increase in the number of macrophages. Inflammatory changes within the 
interstitial tissues increase and this leads to tissue necrosis. At the same time, 
lymphocytes, both mature and blastic, rise in numbers within the graft (Orosz et 
al, 1997). These include T and B lymphocytes and NK cells.
Both CD4^ and CD8^ T cells are present within rejecting grafts, whether 
the graft cells express class I, class II or whole MHC differences (Mayer et al, 
1988). However, the actual numbers of T cells within a graft do not appear to 
related to the speed with which a graft is rejected and this suggests that only a 
small proportion of the cells present may actually have specificity for allogeneic 1s
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antigens. Macrophages within the graft act both as APCs that initiate immune 
responses and as aggressive cells which contribute to graft destruction (Nathan 
and Murray, 1980, Yamamoto et al, 1998). When activated, macrophages produce 
cytokines which in turn activate CD4"  ^ lymphocytes which release cytokines 
themselves. Although NK cells infiltrate allografts rapidly, they have not been 
shown to be critical in allograft rejection. They are unable to bring about organ 
destruction without the participation of T cells (Strom et al, 1977) and thus the 
role of these cells is unclear.
While other cell types may be important in the later, effector stages of 
allograft rejection, it is the antigen-specific action of T cells which initiates 
rejection (Rosenberg and Singer, 1992). The role of T cells in skin graft rejection 
has been extensively studied. Antigen-specific cytotoxic T cells appear to be the 
major effector cells mediating skin allograft rejection, but the generation of 
cytotoxic T cells (Tc) from resting T cell precursors requires lymphokines secreted 
by activated Th cells (Keene and Forman, 1982). Both CD4^ and CD8^ T cell 
populations contain both Th and Tc cells, albeit in different proportions (Swain, 
1983), and Rosenberg et al (1987) demonstrated that immunoincompetent nude 
mice could only reject skin grafts if adoptively-transferred cells reactive against 
the donor skin antigens contained both Th and Tc cells, although these cell types 
could be of identical or distinct phenotypes.
Targeting the CD4 or CD 8 molecule with monoclonal antibodies (mAb) 
to eliminate or inactivate CDd"*" or CD8^ T cells has been used in many different 
experiments. Depleting anti-CD4 antibodies induce long term survival of 
pancreatic islets and vascularised heart allografts but only delay skin graft
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rejection in rodents. Anti-CD8 mAb treatment fails to induce permanent survival 
of heart grafts or pancreatic islets in the rat, and fails to prolongs skin graft 
survival in mice (reviewed in Krieger et al, 1996). Using CD4 and CDS knockout 
mice, Krieger et al demonstrated that rejection of vascularised heart and skin 
grafts can be initiated in the absence of CD8  ^ T cells, but that CD4^ T cells are 
required in allorecognition. Waldmann has demonstrated that non-depleting CD4 
and CD8-specific monoclonal antibodies can induce tolerance to minor 
mismatched skin grafts in mice and that such tolerance is antigen specific (Davies 
et al, 1996). This induction of tolerance using anti-CD4"^ and anti-CD 8  ^antibodies 
alone is, however, strain dependent (Davies et al, 1997) as some strain 
combinations are resistant. It can be concluded, however, that allograft rejection is 
T cell dependent and requires activation of cells with helper function as well as 
activation of cells with cytotoxic function. In many cases, these cell types are two 
distinct populations of T cells which interact with one another (Rosenberg et al, 
1988, Hall, 1991).
1.4.2 The Major Histocompatibility Complex
In all mammalian species there is a single genetic locus which encodes 
antigens which are central to immune recognition and this is termed the major 
histocompatibility complex (MHC). There is great genetic polymorphism within 
the MHC leading to vast differences in the antigens expressed within a population 
(Wood and Morris, 1995). The essential role of MHC antigens is to present 
foreign antigen to responding host T cells. T cell responses are extremely potent 
against allogeneic MHC antigens since approximately 2% of T cells can respond
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to a particular MHC, whereas only around 1 per ten thousand T cells can respond 
to common environmental pathogens (Fischer-Lindahl and Wilson, 1977). Thus 
there is a huge increase in T cell precursor frequency against MHC antigens.
MHC molecules are divided into 3 classes: class I (in humans FIT A-A, - 
B, -C, -E, -F, -G and -H genes), class II (HLA-DR, -DP and -DQ genes), and class 
III which includes genes coding for complement and tissue necrosis factor (Moss 
and Khanna, 1999). Both class I and class II molecules have many common 
structural features. They form stable complexes with peptide antigens, presenting 
them on the cell surface of antigen presenting cells for recognition by T cells. 
MHC molecules are transmembrane glycoprotein heterodimers, formed, in the 
case of class I molecules, by a membrane-bound polymorphic heavy chain (with 
extracellular domains a l ,  a2 and a3) and a soluble, non-polymorphic (32 
microglobulin chain (Bjorlanan & Parham, 1990). Class II molecules are 
composed of membrane-bound polymorphic a  and (3 chains, containing 
extracellular domains a l  and a2, and (31 and (32 respectively. Both class I and 
class II molecules thus have 4 extracellular domains, the 2 membrane-proximal 
domains being immunoglobulin-like structures and the membrane-distal domains 
having a unique structure related to their function.
The three-dimensional structure of the extracellular domains of class I 
and class II molecules has now been determined using X-ray crystallography 
(Madden, 1995, Fremont et al, 1996). The first structure determined for an MHC 
molecule was that of the class I HLA-A2, where the a l  and a2 domains form an 
intrachain dimer, with each domain also contributing to a (3 sheet (Saper et al, 
1991). Two long, interrupted helices, one from the a l  and one from the a2
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domain pack against the (3 sheet, but are separated by an extended groove 
approximately 30A long and 12A wide in the middle, which acts as the peptide 
binding groove. Highly variable residues within the a l  and a2 domains point into
macrophages and dendritic cells, all of which can act as antigen presenting cells
Î
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this groove, conferring unique peptide and TCR binding properties on each MHC 
molecule. Thus the MHC class I allele binds to a spectrum of peptides 8-10 amino 
acids long with high affinity (Jones, 1997). With class II molecules, the peptide 
binding groove is formed as an interchain dimer of the a l  and p i domains. 
Natural ligands for class II molecules are longer than for class I, ranging from 12 
to 25 amino acids in length (Falk et al, 1994).
Despite their similarities, differences between the structures of class I and
class II peptide-binding grooves have important functional consequences. The 
grooves of class I MHC molecules are blocked at both ends, while those of class II 
molecules are open. Thus the ends of peptides presented on class II MHC 
molecules protrude out of the binding groove (Rammensee, 1995), while those on 
class I do not. From a structural point of view, however, an antigenic peptide acts 
as a keystone in the peptide binding domain, placing the peptide at the centre of 
the T cell binding surface.
The tissue distribution of class I and class II MHC antigens differs 
considerably. Class I MHC molecules are found on most nucleated somatic cells 
although levels of expression vary widely between tissues (Harris and Gill, 1986). 
Class II expression is, by contrast, much more limited, with constitutive 
expression being found predominantly on B lymphocytes, monocytes,
Î
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for T cells (Daar et al, 1984). In humans, but not in rodents, class II MHC 
molecules are found on vascular endothelium.
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The primary function of MHC molecules is to scavenge peptides and
express them on the surface of cells for surveillance by T cells. In general , MHC
class I molecules deal with peptides derived from proteins in the intracellular
environment while MHC class II molecules deal with those from the extracellular
,environment (Rammensee et al, 1993). Expression of MHC antigens can be 
augmented or induced by certain cytokines or by stimuli which activate cells. For 
example, IFN-y can induce class II expression on fibroblasts, T cells and 
endothelium (Klareskog and For sum, 1986). TNFa also increases class II 
expression on monocytes and macrophages and has a synergistic effect with IFN-y 
(Arenzana-Seisdedos et al, 1988).
Different functional subsets of T cells are restricted to the MHC antigens 
against which they react. CDd'^ T cells respond to antigen presented in association 
with MHC class II molecules, while CD8”^ T cells respond to antigen associated 
with class I molecules (Davis and Bjoiianami, 1988, Krensky, 1997). CD4 and 
CD8 molecules have been shown to be co-receptors for MHC molecules, with the 
binding sites for both CD4 and CD8 mapping to structurally similar regions of the 
constant domains of MHC class II and class I molecules respectively (Konig et al, 
1992, Salter et al, 1990). The fact that the binding sites for CD4 and CD8 on 
MHC molecules are separate from the peptide-binding domain of MHC molecules 
and, therefore, from the site of interaction with the TCR, shows that a single MHC 
molecule can be bound by both TCR and CD4 or CDS simultaneously, and this 
increases the overall avidity of the interaction (Zomoyska, 1998).
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1.4.3 T Cell Activation
T cells cannot be stimulated by soluble foreign antigens but rather require 
that antigen is presented to them on the surface of specialised APCs (Grewal and 
Flavell, 1998). This involves the breakdown of foreign proteins by APCs into 
peptides which are then associated with host MHC molecules and presented on the 
surface of the APC. T cells, via the T cell receptor (TCR), can then interact with 
these cells (Krensky et al, 1990). APCs such as dendritic cells, macrophages and B 
cells all express MHC class II antigens and so can stimulate CD4"  ^ T cells when 
antigen is presented associated to class II molecules. In addition, APCs 
communicate with T cells via other cell surface co-stimulatory molecules which 
are necessary for T cell activation (Grewal and Flavell, 1998, Lenschow et al, 
1996).
For T cell activation to occur, there must be 2 signals: signal 1 involves 
TCR engagement with the MHC antigens on the APC while signal 2 involves the 
interaction of co-stimulatory molecules on the surface of both the T cell and the 
APC (Janeway and Bottomly, 1994, Jenkins, 1994). On activation of the T cell, 
there is a cascade of intracellular second messengers culminating in the 
transcription of genes responsible for mediating the effector functions of the T 
cell.
One such important co-stimulatory molecule is the CD28/B7 complex 
with the CD28 molecule on the T cell and the B7 complex on the APC (June et al, 
1994, Chambers and Allison, 1997). Two ligands, B7-1 and B7-2, have been 
identified for CD28, B7-1 being expressed on activated B cells, dendritic cells and 
monocytes, while B7-2 is expressed on resting monocytes. Blockade of this
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pathway prevents T cell activation (Harding et al, 1992), inducing a state of 
unresponsiveness or anergy, preventing differentiation and proliferation of T cells. 
CD40, another co-stimulatory molecule has also been shown to play a role in T 
cell activation, as well as in activation of APCs (Grewal and Flavell, 1998, Larsen 
and Pearson, 1997). CD40 is expressed on B cells and many other APCs including 
dendritic cells, macrophages and endothelial cells and CD 154, the ligand for 
CD40 is expressed on T cells. Activated T cells rapidly express CD154 in 
response to TCR ligation (Roy et al, 1993). Recent evidence suggests that by 
antagonising the CD40/CD154 interaction, T cell priming and clonal expansion is 
prevented (Grewal and Flavell, 1998), suggesting that such co-stimulatory 
molecules are important in T cell activation. In addition, interaction between 
CD40 on B cells and CD40 ligand on activated T cells up-regulates B7 expression 
on B cells, thereby increasing T cell co-stimulation (Chamber and Allison, 1997). 
Thus, by preventing the interaction of these co-stimulatoiy molecules, T cell 
activation can be prevented, and this has been employed as a strategy to alter T 
cell responses in allograft rejection (e.g. Larsen and Pearson, 1997, Forster et al, 
1999).
1.4.4 Presentation of Antigen
As already stated, T cells recognise antigens as processed peptides 
presented in the context of self MHC molecules and this is termed MHC 
restriction. APCs internalise foreign antigen and break it down into peptide 
fragments. These are then presented in the peptide-binding grooves of MHC 
molecules on the surface of the APC for recognition by host T cells (Wood and
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Morris, 1995). Presentation of such peptide in a meaningful manner is only 
accomplished by a few specialised APCs, including dendritic cells, macrophages, 
B cells and endothelial cells (Germain, 1993). However, in transplanted tissue 
there is the unique situation where there are 2 sources of APC, that is either host 
derived which can process donor antigen and present it with self MHC, or donor 
derived which will present donor MHC. Host T cells can engage and respond to 
the high levels of donor MHC antigens expressed on donor APCs and these cells 
also provide the appropriate co-stimulatory signals to the host T cells. This is 
termed direct presentation (Cramer and Shirwan, 1998). Thus alloreactive T cells 
recognise peptides, either exogenous or endogenous, bound to a particular allo- 
MHC molecule or recognise the allo-MHC molecule itself. This may explain why 
there is such a high precursor frequency to allogeneic MHC (Heber-Katz et al, 
1982, Lui et al, 1993). Direct recognition therefore induces a rapid and vigorous 
immune response which results in aeute allograft rejection (Cramer and Shirwan, 
1998, Benichou et al, 1999).
Allogeneic MHC molecules can also be processed by host APCs and thus 
presented as antigen bound to host MHC molecules, as in a normal immune 
response. Host T cells can recognise these allo-MHC-derived peptides presented 
with host MHC and this is termed indirect presentation. There is now increasing 
evidence that indirect presentation can play a role in allograft rejection (Bradley et 
al, 1992, Shoskes and Wood, 1994, Bradley, 1996, Valujskikli et al, 1998).
Sensitisation of host T cells may occur within the graft itself or else in the 
draining lymph node. Barker and Billingham (1967) demonstrated that donor 
APCs will migrate out of the graft to the regional lymph node where they will
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encounter a large number of host T ceils. Such migrating APCs have been termed 
“passenger leulcocytes” and play an important role in the presentation of donor 
antigen to the host immune system.
1.5 T-helper Cells and Production of Cytokines
T cells play a central role in allograft rejection and they have been 
divided into a number of different types, being characterised in a number of 
different ways. Mosmann et al (1986) were, however, the first to characterise such 
cells on the basis of the different cytokines which they produce, attributing 
specific fimctions to the different cell types. According to the dominant cytokines 
which they produced, mouse CD4^ T cell clones were divided into 3 groups: T 
helper 0 cells (ThO), T helper 1 cells (Thl) and T helper 2 cells (Th2).
Mouse Thl cells produce Interleukin 2 (IL-2), Interferon-y (IFN-y) and 
Tumour Necrosis Factor-(3 (TNF-(3), while Th2 cells produce IL-4, IL-5, IL-6, IL-
9, IL-10 and IL-13 (Mosmann and Sad, 1996). Similar patterns have been 
observed in human T-cells, although the synthesis of IL-2 , IL-6 and IL-10 may
not be as strictly limited to Thl and Th2 cells as in the mouse (Del Prete et al,
-
1991). Thl and Th2 cytokine secretion patterns represent activated effector cell 
phenotypes which have been generated during an immune response. ThO cells 
produce a variety of cytokines common to both Thl and Th2 cells, namely IL-2,
IL-4 and IFN-y (Mosmann and Sad, 1996).
T
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1.5.1 Differentiation of T-helper Cells
When first stimulated by antigen presented on an antigen presenting cell, 
naive T cells produce IL-2 and then differentiate into cells which produce other 
cytokines (Mosmann and Sad, 1996, Swain, 1999). This is summarised in figure 
1.2. The differentiation of ThO cells appears to be dependent on the cytokines 
present at the time of antigen presentation. For example, by blocking 
differentiation of naive T cells using TGF-p and anti-IFN-y antibody, CD4'^ T 
cells are kept in a proliferating state (Sad and Mosmann, 1994). When these cells 
are subsequently re-stimulated with specific cytokines they will then differentiate: 
the presence of IL-4 results in the generation of Th2 cytokine production while the 
presence of IFN-y induces Thl cytokine production. Thus Thl and Th2 cells can 
be derived from a common precursor cell (Mosmami and Sad, 1996) with specific 
cytokines promoting the differentiation into a Thl phenotype and others 
promoting a Th2 phenotype. Thus the pattern of cytokines present during the 
initial stimulation of naïve Th cells dictates whether ThO cells will develop into 
Thl or Th2 cells.
IFN-y, and the subsequent down regulation of IL-4 promotes the 
development of Thl cells (Hsieh et al, 1993, Gajewski et al, 1989). Another 
cytokine, IL-12 can promote Thl differentiation independently, and also increases 
IFN-y production by NK cells and T-cells, which further encourages a Thl 
phenotype (Trinchieri, 1993). Positive feedback mechanisms therefore exist to 
amplify cytokine production, further polarising the Thl response. An additional 
cytokine, interferon y-inducing factor (IGIF), also laiown as IL-18, has recently 
been identified and it appears to synergise with IL-12 in inducing IFN-y
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production by both differentiating and committed Thl cells (Robinson et al, 1997, 
Okamura et al, 1998). It also induces IFN-y production by NK cells (Ushio et al, 
1996), indicating that both IL-12 and IL-18 are required for maximal expression of 
the Thl phenotype. Conversely, the generation of Th2 cells is critically dependent 
on the presence of IL-4 (Seder and Paul, 1994, Swain et al, 1990). This induces 
further IL-4 production by T cells in an analogous feedback loop.
One important factor in the Thl/Th2 paradigm is that once a specific 
direction is determined early in the immune response, it remains stable unless 
major changes take place in the balance of cytokine production (Mosmann and 
Sad, 1996). This is due to the fact that cytokines exert negative feedback on the 
cells which produce antagonistic cytokines, IL-12 and IFN-y inhibit the 
differentiation and effector functions of Tli2 cells and prevent production of IL-4 
(Liblau et al, 1995). IL-4, IL-10 and IL-13 inhibit Thl cell proliferation and 
oppose the effects of IFN-y on macrophages (D’Andrea et al, 1993). Thus cross- 
regulatory interactions occur which further polaiise the immune response with IL- 
12 and IFN-y being the most important cytokines for inhibition of a Th2 
phenotype and IL-4 the most important for inhibition of Thl responses (Trinchieri, 
1995).
In the primary response, antigen-specific T-cells are present at low 
concentrations and so other cell types probably secrete the cytokines which 
influence T-cell differentiation. IL-12 is synthesised by many cell types including 
macrophages and B cells (Gately et al, 1998). Natural killer (NK) cells synthesise 
IFN-y in response to IL-12 (Trinchieri, 1993) or in response to antigen-mediated 
cross linking of antibody bound to Fc receptors (Trinchieri, 1989). In mice, early
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production of IL-4 may be due to mast cells, basophils and some T-cells 
(Yoshimoto and Paul, 1994). Thus, the cytokines which determine the polarisation 
of the immune response into Thl or Th2 are produced by the cells of the innate 
immune system early after exposure to antigen (Bogen et al, 1993).
The type of antigen presenting cell involved appears to be less important 
in Thl versus Th2 differentiation than the types of cytokine present as dendritic 
cells, macrophages and B cells are capable of inducing Thl or Th2 phenotypes in 
the presence of the appropriate cytokines. However, co-stimulatory molecules on 
APCs may also influence differentiation (Thomson, 1995, Abbas et al, 1996, 
O’Garra, 1998).
1.5.2 Functions of T-helper Cells
The in vivo relevance of the functional division of Th cells into different 
subsets has been extensively studied. Thl cells are predominantly involved with 
cell-mediated immune responses. Delayed type hypersensitivity (DTH) is an 
inflammatoiy reaction mediated by the products of T cells (Hall, 1991). In an 
experimental system in which T cells plus antigen were injected into the footpads 
of mice, only Thl clones were able to elicit antigen-specific swelling suggesting 
that Thl cells are responsible for the generation of DTH (Cher and Mosmami, 
1987). The DTH reaction may involve 2 phases with an initial activation signal 
resulting in recruitment of effector T cells into the site and these cells then recruit 
monocytes and granulocytes which mediate the subsequent stages of the reaction 
(Van Loveren et al, 1984). Thl cytokines activate macrophages and NK cells
I
(Romagnani, 1992) and activate cytotoxic T lymphocytes which, in turn, can
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synthesise further Thl-type cytokines, amplifying the response (Mosmann and 
Coffman, 1989). Thus Thl responses promote cell-mediated events and these have 
been proposed as central in allograft rejection (Piccotti et al, 1997, a).
As well as generation of cell mediated responses, Thl cells have a role in 
B cell help. Thl clones at low antigen concentrations can activate B cells to 
produce specific IgG isotypes. Thl clones induce the production of IgG 2a 
(Coffman et al, 1988). IFN-y, a Thl cytokine, appears to be important for high 
levels of IgG 2a production, but other factors may also be involved. IFN-y induces 
increased expression of Fc receptors for IgG 2a (Warren and Vogel, 1985) leading 
to increased antibody dependent macrophage cytotoxicity. In addition, IgG 2a can 
kill target cells by complement lysis.
Conversely, Th2 cells provide optimal help for humoral immune 
responses (Mosmami and Sad, 1996). Th2 clones induce proliferation and Ig 
secretion by B cells and activate populations of small resting B cells. Growth and 
differentiation of B cells requires direct contact with Th2 cells, while optimum 
proliferation and differentiation require both IL-4 and IL-5 (Mosmann and 
Coffman, 1989). IL-4 encourages IgE production as well as increased expression 
of IgE Fc receptors on B cells, while IL-5 causes proliferation of eosinophils. In 
addition, Th2 cells promote mucosal immmiity thi'ough mast cell proliferation and 
facilitation of IgA synthesis. Thus Tli2 clones induce IgM, IgG, IgA and IgE 
synthesis by B cells and have no cytolytic potential (Romagnani, 1994) while Thl 
clones result in delayed type hypersensitivity with little antibody production.
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1.6 Transplantation Tolerance
A large amount of research has been carried attempting to influence the 
recipient immune system by altering T cell function, and so render the host 
um’esponsive, or tolerant, to an allograft. Tolerance can be defined as the 
indefinite survival of a graft in the absence of ongoing immunosuppression in the 
presence of an otherwise intact immune system and normal host defences 
(Charlton et al, 1994). Numerous strategies have been developed and successfully 
applied to achieve allograft tolerance in rodent models. Various mechanisms have 
been proposed to attempt to explain transplantation tolerance, and the 
predominance of one particular mechanism may be a result of many variables. 
Such mechanisms have been classified as central i.e. operate within the thymus, or 
peripheral i.e. operate outside and independently of the thymus.
Intrathymic events are of great importance in the development and 
maintenance of self-tolerance. The stromal elements of the thymus, including the 
bone marrow-derived and epithelial constituents, are capable of influencing the 
repertoire of emigrating, mature T cells. Tluough deletion due to apoptosis, and 
silencing by functional inactivation, T cells with anti-self reactivities aie 
prevented from leaving the thymus (Kappler et al, 1988). However, important as 
central mechanisms are for self tolerance, long term graft acceptance can be 
achieved independently of thymic involvement either by treatments which alter 
the recipients immune system or by pre-treatment of the donor tissue (Lafferty et 
al, 1986, Waldmami et al, 1993). In such cases peripheral mechanisms of 
tolerance are responsible for controlling the rejection response. Several distinct 
mechanisms for peripheral tolerance have been proposed.
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1.6.1 T Cell Ignorance
were employed, it has not been described as an ongoing mechanism of graft
As already stated, T cells aie activated by cross-linldng of their TCR 
following the recognition of specific target antigen / MHC complexes presented 
by APCs. T cells are able to respond if antigen is presented by “professional” 
APCs. However, if a graft is devoid of such APCs, antigen may be presented by 
“non-professional” APCs which fail to stimulate any response from T cells with 
the appropriate TCR, leading to T cell ignorance and graft acceptance (Miller et 
al, 1990). Such a situation arises when tissue grafts such as thyroid or pancreatic 
islets are maintained in vitro prior to grafting (Lacy et al, 1979, Lafferty et al, 
1986). The period in culture is thought to rid the graft of professional APCs (or 
passenger leukocytes) which migrate out of the graft and thus the allograft 
provides no stimulus to activate recipient T cells. However, while this technique is 
effective in tissue culture, it is more difficult to achieve the same results with 
whole organ grafting.
1.6.2 Deletion
As already stated, T cells able to recognise antigenic self-MHC in the 
thymus can be programmed to die thi'ough apoptosis and this is central to the i
maintenance of self-tolerance. Apoptotic deletion of mature T cells can, however, 
also occur in the periphery. This has been identified as the mechanism responsible 
for the induction of tolerance to superantigens following infusion of leukocytes 
into thymectomised adult mice (Webb et al, 1990). Despite this, while deletion of
reactive T cells has been described after transplantation when therapeutic agents
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tolerance and its role in transplantation tolerance does not appear to be significant 
(Charlton et al, 1994).
1.6.3 Anergy
Anergy in T cells was first described by Lamb et al (1983) who 
demonstrated that T cell clones exposed to antigen expressed on other T cells in 
culture failed to proliferate in response to subsequent re-exposure to the antigen 
presented by normal APCs. This functional uni'esponsiveness, termed T cell 
anergy, can result from antigen receptor stimulation in the absence of a second, 
co-stimulatory signal (Chambers and Allison, 1997). As already stated, T cell 
activation requires 2 separate signals: signal 1 involves TCR engagement with the 
APC while signal 2 requires the interaction of co-stimulatoiy molecules on the 
surface of the APC and the T cell.
Much attention has recently focused on the CD28/ B7 interaction. The B7 
ligand has 2 forms, B7.1 and B7.2. B.71 is expressed on dendritic cells and at low 
levels on resting APCs and lymphocytes while B7.2 is expressed at low levels on 
resting APCs and moderate levels on resting T cells. Both ligands are up-regulated 
upon activation (June et al, 1994). CD28 is present on virtually all T cells and its 
expression is up-regulated during activation. Stimulation through CD28 induces 
IL-2 production, proliferation of T cells and enliances cell-mediated cytotoxicity 
(Lenschow et al, 1996), while blockade of the B7/ CD28 interaction inhibits 
proliferative responses to alloantigen (Tan et al, 1993). In vivo blockade of the 
B7/CD28 interaction has been achieved by the use of CTLA 4-Ig, a soluble form 
of CTLA 4, an alternative B7-binding T cell molecule. Thus T cells receive signal
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1 but not signal 2, and are therefore inactivated This has been shown to be 
effective in vivo as treatment with CTLA 4-Ig prevents cardiac allograft rejection 
(Turka et al, 1992) and produces tolerance to xenogeneic islet grafts in mice 
(Lenschow et al, 1992).
Other measures are also capable of inducing anergy in vivo.
evidence that development of a Tli2 like cytokine environment is critical for the 
induction of tolerance to alloantigen (see below).
Administration of cell types which do not provide second signals is a well
established technique. Such non-professional APCs present the antigenic peptide-
MHC complex, but lack the co-stimulatory cell surface molecules to induce T cell
activation. Pre-treatment of graft recipients with donor antigen in the form of a
blood transfusion uses this mechanism (Dallnian et al, 1991, a). Other workers
have used gene transfection experiments to induce unresponsiveness (e.g. Madsen
et al, 1988) and a number of adhesion molecule-blocking antibodies are also
effective in inducing anergy, such as those directed at CD 4, LFA-1 and ICAM-1
(Wood and Morris, 1995).
Anergy is thus defined as a proliferative uni'esponsiveness and the
cytokine environment may also play a role in influencing this. It has been
.suggested that the Th2 cytokines IL-4 and IL-10 may be associated with 
unresponsiveness (Takeuchi et al, 1992), or that low or defective production of 
Thl cytokines might also be responsible (Dallman et al, 1991, a). Many studies 
have shown that there is a difference in cytokine expression in rejecting and 
tolerant recipients (e.g. Bugeon et al, 1992) but, as yet, there is only indirect
:
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1.6.4 Suppression
The term suppression has been used to describe a situation whereby 
potentially alio-reactive T cells are present but are prevented from responding by 
other cell populations. Antigen specific suppressors can be defined as cells which 
inliibit effector responses by recognition of the same antigen. These cells can be 
adoptively transferred from animals bearing long term allografts to a naive, 
syngeneic recipient and modify the rejection response to a fresh graft (Hutchison, 
1986). For example, adoptive transfer of CD4"  ^T cells from rats tolerant to kidney 
allografts render naive rats tolerant (Hall et al, 1984).
Evidence for active regulatoiy cells maintaining peripheral tolerance has 
come from adoptive transfer studies where injection of lymphocytes from an 
animal tolerised to a specific allograft into a T cell-depleted host can prevent 
injected T cells from an untreated animal rejecting an identical graft. CD4^ T cells 
were found to be the active suppressor cells (Qin et al, 1993, Davis et al, 1996). 
Chai et al (1999) demonstrated that anergic T cells adoptively transferred into 
mice can induce prolongation of skin graft survival, indicating that anergic T cells 
can act as suppressor cells. Interestingly, they found that this suppression was not 
mediated by increased Th2-type cytokines, but other workers have found that the 
cytokine environment is important in suppression. Davis et al (1996) found that in 
a model of allogeneic skin grafting in mice, the presence of IL-4 was at least 
partially responsible for the suppressive effect. Similarly, Yang, L. et al (1998) 
demonstrated that, in a model of tolerance to an allogeneic skin graft induced by 
donor-specific transfusion in mice, the mechanism of tolerance was the generation 
of a population of suppressor cells. In this situation, tolerant animal were found to
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have significantly elevated levels of IL-4 in their serum compared to controls. In 
another model of tolerance induced by donor-specific transfusion and anti-CD4 
mAb treatment (Roelen et al, 1998), tolerance was mediated by a population of 
CD4^ T cells acting as suppressor cells. The authors suggested that CD4^ T cells 
from such animals produce increased amounts of IL-10 on re-stimulation, 
indicating that the Thl/Th2 paradigm may be relevant in the suppression 
phenomenon.
1.6.5 Donor-specific transfusion
Donor specific blood transfusion (DST) or donor antigen pre-treatment has 
been used extensively as a method for prolonging allograft survival in 
experimental models. In addition, it has been observed that patients who received 
multiple blood transfusions prior to renal transplantation have improved rates of 
graft survival compared to those who have not (Dossetor et al, 1967, Opelz et al, 
1973, Persign et al, 1979 and Chavers et al, 1997). It has also been demonstrated 
that transfusion of patients with donor blood prior to renal transplantation 
increases allograft survival (Singal et al, 1985, Salvatierra et al, 1980). Others 
have shown that DST reduces the frequency of acute rejection episodes in the 
early period after transplantation (Bayle et al, 1995, Opelz et al, 1997) and that 
CD4^ T cells are involved in this transfusion effect (Van Rood and Claas, 1990). 
However, some studies have demonstrated that DST may actually sensitise 
patients, inducing the production of alloantibody, and this has deleterious effects 
on allograft survival (Opelz, 1985, Burlingham et al, 1989). In an effort to avoid 
sensitising patients to donor antigen at the time of DST, other workers have pre­
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treated patients with DST plus immunosuppressive agents (Alexander et al, 1992, 
Alexander et al, 1993) and have demonstrated improved graft survival. More 
recently, Reinsmoen et al (1999) reported that patients treated with DST around 
the time of renal transplantation showed donor antigen-specific hyporeactivity in 
vitro compared to controls which had not received DST.
Cells derived from a variety of lymphoid tissues, as well as whole blood 
transfusion have been used to induce specific unresponsiveness to alloantigen in 
adult rodent models (e.g. Takeuchi et al, 1992, Cranston et al, 1986). In rodents, 
peripheral blood lymphocytes, erytlirocytes and platelets have all been shown to 
be capable of inducing uni'esponsiveness in vivo (Wood and Morris, 1985), 
although studies using different lymphocyte subpopulations have produced
conflicting results. Cranston et al (1986) found that B cells and CD4^ T cells were 
effective, whereas more recently Gorczynski et al (1996, b) have demonstrated 
that purified dendritic cells are effective. The critical factors for the induction of 
unresponsiveness rather than sensitisation following pre-treatment with 
alloantigen are the route and timing of antigen administration relative to grafting 
(Bradley, 1991). Intravenous delivery of antigen often results in unresponsiveness 
and, if  antigen alone is used, a finite time after antigen administration is required 
before a beneficial effect is seen.
In spite of much effort attempting to elucidate the mechanism responsible 
for the transfusion effect, clear evidence for a single underlying mechanism has 
not been found. This is partly explained by the great variety of model systems 
examined, the variable factors in different allografts and the complexity of the 
allograft rejection response. Some workers have suggested that pre-treatment with
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donor antigen promotes a protective Th2 alloimmune response and, at grafting, 
this Th2 response is strengthened and so rejection is prevented. In support of this, 
Babcock and Alexander (1996) demonstrated that spleen cells harvested from 
transfused animals produce increased amounts of IL-4 and IL-10, and reduced 
levels of IL-2 when re-stimulated with mitogens in vitro. Others have 
demonstrated a decrease in Thl cytokine production by re-stimulated splenocytes 
from animals treated with donor-specific transfusion (Dallman et al, 1991, a). 
Following blood transfusion, macrophages produce increased amounts of IL-10 
and prostaglandin E2 (Takeuchi et al, 1992) and this may promote activation of 
Th2 clones and inhibit the generation of Thl cytokine producing cells. Josien et al 
(1995) demonstrated that, following DST which tolerises the recipient to an 
allogeneic heart graft, graft infiltrating cells are unable to produce a variety of 
cytokines including IL-2 and IFN-y, compared to unmodified graft recipients 
where such cells exhibit strong expression of such cytokines.
Other workers have demonstrated that DST results in the generation of
immunoregulatory T cells. Yang, L. et al (1998) described how DST in a TCR-
transgenic mouse skin graft model resulted in permanent allograft survival. They
suggested that DST promotes the induction of suppressor cells, dependent on the
presence of IL-4, and these inhibit the activation of donor-reactive T cells. In
.addition, DST promotes IL-4 production in recipient animals, stimulating these 
suppresser cells. Roelen et al (1998) suggested that DST, in combination with 
anti-CD4 mAh, a regime which tolerises mice to an allogeneic heait graft, results
responses. Interestingly, DST is successful in prolonging allograft survival when
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4.in the generation of immunoregulatory CD4 T cells which inliibit allospecific I:
the effector stage of rejection is a cell mediated event, but not when it is an 
antibody mediated event (Yang, C.P. et al, 1998). This is supported by the finding 
that tolerance to a heart allograft in a rat model induced by DST can be abolished 
by the administration of recombinant IFN-y, but that this is associated not with an 
increase in aThl-type cytokine response but by alloantibody production (Josien et 
Ed, 1999).
The persistence of donor antigen within the graft recipient may also be 
critical for the induction of allospecific tolerance. While an allograft survives 
within the recipient, donor antigens are continually shed into the recipient and 
here they may inactivate newly emerging T cells from the recipients thymus 
(Wood and Morris, 1995). This has been supported by the observation that, after
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removal of a graft, if the recipient is rechallenged with the same antigen some
.time later, tolerance is lost (Shizuru et al, 1990) indicating the ongoing need for 
the presence of donor antigen within the recipient.
It has been proposed that the development of microchimerism within the 
host is important for the induction and maintenance of tolerance (Bushell et al, 
1995). The authors addressed this issue by examining donor-specific transfusion 
in a mouse cardiac allograft model where peripheral tolerance could be induced by 
a combination of injection of viable donor-specific cells plus anti-CD4 mAh. They 
found that when donor cells are irradiated prior to injection, graft survival is not 
prolonged. They concluded that when unmodified donor cells plus anti-CD4 mAh 
are given together, donor reactive T cells still encounter antigenic cells but are 
unable to react due to blocking of the second signal by anti-CD4 mAb and this 
leads to T cell unresponsiveness and the graft is not rejected. However, when
....
irradiated cells are injected, they fail to survive for long enough for these abortive 
T cell encounters to occur, and so, when a graft is added, normal T cell responses 
occur and the graft is rejected. When repeated injections of irradiated donor cells 
are given around the time of anti-CD4 antibody treatment, tolerance is induced, 
indicating that non-viable cells can induce tolerance as long as they persist within 
the host for sufficient time.
1.7 T h l/ Th2 Paradigm in Transplantation
The hypothesis has been proposed that therapies which induce immune 
deviation from a Thl to a Th2 response early during the allograft response will 
result in graft tolerance or prolonged survival of the graft (Piccotti et al, 1997, a). 
This arose from the observation that allograft rejection is often associated with a 
Thl response, while tolerance is often associated with a down regulated Thl 
response and an increased Th2 response. The Thl cytokines, IL-2 and IFN-y, as 
well as the CTL-specific marker granzyme B have all been detected in hosts 
undergoing unmodified allograft rejection (Dallman et al, 1991, b, Takeuchi et al,
1992). Takeuchi et al demonstrated that, by treating mice with donor specific 
transfusion, cyclosporin or anti-CD4 monoclonal antibodies, they could be 
tolerised to accept an allogeneic heart. When the grafted hearts and recipient 
spleens were analysed, there was greatly reduced RNA message for IL-2 and IFN- 
y, and enhanced levels of message for IL-4 and IL-10. It was concluded that 
peripheral tolerance is linked to the differential activation of Th2 cells. In 
addition, adoptive transfer of cells from the spleens of tolerant animals prolonged 
heart graft survival in naive recipients and these cells were of the Th2 phenotype.
i
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Dallman et al (1991, a) demonstrated that administration of IL-2 prevents long 
term graft survival when given to animals which have received a normally 
tolerising regime of anti-CD4 antibody plus donor specific transfusion. Peripheral 
tolerance in a rat model was also seen to be associated with reduced levels of IL-2 
and IFN-y production (Bugeon et al, 1992).
Rats pre-treated with a single injection of CTLA 4-Ig ai'e tolerised to a 
renal allograft in 70% of cases (Sayegh et al, 1995). In tolerant animals, 
immunohistological analysis reveals that IFN-y expression is reduced while IL-4 
expression is increased compared to controls. Treatment with IL-2 following the 
tolerising therapy partially prevents long term engraftnient.
Gorczynski and Wojcik (1994) demonstrated that pre-treatment of mice 
with irradiated donor specific splenocytes, injected via the portal vein, prolongs 
skin graft survival. When lymphocytes are removed from such animals and 
stimulated in vitro they produce increased levels of IL-4 and IL-10 with decreased 
IL-2 and IFN-y. Cells from control grafted animals re-stimulated in vitro produce 
high levels of Thl cytokines and low levels of Th2 cytokines, suggesting that 
preferential activation of Th2 cells is linleed with prolonged allograft survival. In 
addition, in adoptive transfer studies, Th2-cytokine producing cells prolong skin 
graft survival when they are injected into mice pre-treated with donor cells via the 
portal vein (Gorczynski et al, 1996, a). More recently, Saggi et al (1999) 
demonstrated that tolerance to a renal allograft in a rat model induced by 
rapamycin and cyclosporine was associated with up-regulated IL-4 and IL-10 
production, and that IFN-y was only detectable in grafts showing evidence of 
rejection.
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While these results lend support to the idea that Tli2 activation equates
with tolerance, other studies have failed to confirm this. In another model of
tolerance to heart grafts in rats induced by donor specific transfusion, low levels of
transcripts for both Thl and Th2 cytokines are detected, thus failing to
demonstrate any up-regulation of a Th2 response (Josien et al, 1995). Other
studies have even demonstrated that a Th2 response may be associated with
rejection, albeit somewhat delayed (Chan et al, 1995). In a study of pig islet
.xenografting into mouse recipients, rejection is associated with activation of Th2
.responses, while tolerance is associated with reduced IL-4 expression. In addition, 
tolerance induced by anti-CD4 mAb therapy could be reversed and this is 
associated with an increase in IL-4 expression (Morris et al, 1995). Other workers 
have also demonstrated that Th2 cells alone are capable of mediating allograft 
rejection. VanBuskirk et al (1996) demonstrated that transfer of either alloreactive 
Thl or Th2 cells could effect allograft rejection in athymic SCID mice. They 
demonstrated that both cell types can bring about rapid, acute rejection of grafts 
and that the transferred cells are found in the rejecting graft.
1.7.1 Treatment with Cytokines
.Various workers have attempted to manipulate the cytokine environment 
directly at the time of alio antigen exposure in order to influence the fate o f an 
organ or tissue allograft. Levy and Alexander (1995) assessed the effects of 
intragraft infusion of recombinant IL-4 or IL-10 using an osmotic minipump in a 
rat heart allograft model which had been pre-treated with cyclosporin. They found
Î
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athat when rats are treated with IL-10 there is no effect on graft survival, but in the 
animals treated with IL-4 there is a significant prolongation in graft survival.
Gorczynski et al (1995) found that in their model of prolonged skin graft 
survival in mice where recipient animals are pre-treated with donor-strain 
splenocytes injected via the portal vein prior to grafting, increased graft survival is 
associated with an up-regulated Th2 response and a down regulated Thl response, 
with increased IL-4 and IL-10 production and decreased IFN-y and IL-2 
production by immunocompetent cells from treated animals re-stimulated in vitro 
by donor antigen. However, prolongation of graft survival can be prevented by 
treatment with anti-IL-10 antibody plus recombinant IL-12. In addition, this 
induces a switch from a Tli2 to a Thl cytokine production pattern when cells are 
re-stimulated in vitro, with increased IL-2 and IFN-y and reduced IL-4 and IL-10 
production. Qin et al (1996) described a gene transfer model in mice, in which 
treatment with a retrovirus producing IL-10 significantly prolongs survival of a 
cardiac allograft. They demonstrated that retro-viral mediated gene transfer of 
viral IL-10 prolongs graft survival in a non-vascularised neonatal cardiac 
transplant model. Interestingly, this method has also been applied to a vascularised 
cardiac transplant model in which a plasmid encoding viral IL-10 is perfused 
through the graft. This viral IL-10 gene transfer significantly prolongs heart graft 
survival and is associated with a decrease in Th, Tc and alloantibody responses 
(Piccotti et al, 1997, a).
Other workers have been less successful when using cytokine therapy. IL- 
10 treatment of mice grafted with allogeneic hearts produces a slight increase in
graft survival (Lowry et al, 1995). However, others have found that treatment with I
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IL-10, modified to prolong its half-life within the host, does not prolong survival 
of murine pancreatic islets (Zheng et al, 1995).
In an attempt to elucidate the precise role of cytokines in transplantation, 
the ability of mice bearing disruptions to the genes encoding for specific cytokines 
to reject allografts has been examined. Mice deficient in IL-2 production reject 
pancreatic islet grafts, although rejection is delayed compared to wild type 
controls (Steiger et al, 1995). However, IFN-y is strongly expressed in these grafts, 
suggesting that a switch to a Tli2 response has not occurred. IFN-y or IL-4 
knockout mice are both able to reject cardiac allografts (Strom et al, 1996). IL-12 
knockout mice have also been examined (Piccotti et al, 1998). Cardiac allografts 
are rejected more rapidly in IL-12 Icnockout mice than in wild-type controls. 
Interestingly, however, these mice are still capable of producing both IFN-y and 
Thl cells, indicating that IL-12 is not essential for the generation of a Thl 
response. These results are, however, difficult to interpret as the immune systems 
of such mice may not be directly comparable to wild type controls.
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1.8 Interleukin-12
As manipulation of certain cytokines has not demonstrated conclusive 
support for a Th2 switch being required for allograft survival, attention has turned 
to other cytokines. IL-12, with its key role in the differentiation and maintenance 
of Thl cells and its inlhbition of Tli2 cells (Gately et al, 1998), is an obvious 
choice as a target molecule to assess the influence of the Thl/Th2 paiadigm in 
allograft rejection.
IL-12 is a heterodimer, composed of two covalently linked glycosylated 
chains, one of 40 kDa and the other of 35 kDa which are encoded by separate 
genes (Wolf et al, 1991). The p35 light chain has limited homology with IL-6  
while the p40 heavy chain is not homologous with any other cytokine and most 
closely resembles the IL- 6  receptor. It belongs to the haemopoietin receptor family 
and resembles the extracellular domain of the IL-6  receptor a-subunit. Thus it is 
possible that the covalently linked IL-12 heterodimer is derived from a primordial 
cytokine of the IL- 6  family covalently linlced to the soluble form of its own 
receptor (Trinchieri, 1993).
.The IL-12 receptor chains are expressed mainly by activated T cells and :
,NK cells. Two IL-12 receptor chains have so far been identified, termed [31 and [32 
because they share the general features of [3 type cytokine receptors, each 
belonging to the gp 130 subgroup of the cytokine receptor superfamily (Wang et 
al, 1999). Each chain alone binds IL-12 with low affinity, but when both chains 
are expressed together, they bind IL-12 with high affinity (Piccotti et al, 1999).
Thl and Th2 cells both express the IL-12 [31 receptor chain, but only Thl cells i
express the [32 chain and this accounts for the inability of Tli2 cells to respond to
■I
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IL-12 (Lamont and Adorini, 1996). In addition, expression of the IL-12 receptor 
P"2 chain appears to be regulated by cytokines such as IL-10 and TGF-(3 (Wu et 
al, 1997). Thus control of this receptor chain expression may constitute a pivotal 
mechanism for regulating IL-12 responsiveness.
1.8.1 Production of Interleukin-12
IL-12 is produced mainly by dendritic cells, macrophages and neutrophils 
and production can be induced by their interaction with activated T cells which 
provide co-stimulatory signals (Shu et al, 1995, Maruo et ai, 1997). Kératinocytes 
and Langerhans cells are capable of low levels of IL-12 production (Trinchieri, 
1993). Thus IL-12 is produced primarily by antigen presenting cells and exerts 
immunregulatory effects on both T and NK cells, inducing production of large 
amounts of IFN-y (Gately et al, 1998).
1.8.2 Effects of Interleukin-12
IL-12 acts at different stages in the immune response, being involved in 
both its induction and maintenance by regulating the balance between Thl and 
Th2 cells. In vitro, it has stimulatory effects on NK cells and T cells and these 
include induction of transcription and secretion of cytokines. IL-12 stimulates 
both NK and T cells to produce increased levels of IFN-y (Chan et al, 1991). This 
induction of IFN-y leads to an antagonistic effect on the production of IL-4 
(Heinzel et al, 1993) and so IL-12 promotes Thl cytokine production while 
inliibiting the generation of Tli2 cytokines. In addition, IL-12 itself may promote 
the differentiation of naive T helper cells into Thl cells. When highly purified
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CD4^ T cells are cultured with immobilised anti-CD 3, without APCs, IL-12 
enhances priming for IFN-y production implying that IL-12 can act directly on the 
naive T-helper cell (Hsieh et al, 1993). In addition, neutralising IFN-y using anti- 
IFN-y antibodies does not diminish IL-12-mediated priming for IFN-y production, 
indicating that IL-12 does act directly on the naive T-helper cell to induce 
differentiation into a Thl cell (Seder and Paul, 1994).
As well as inducing cytokine production, IL-12 enhances NK cell 
cytotoxic activity and activates macrophages (Chan et al, 1991). Allospecific 
CD8  ^ cytotoxic T lymphocytes proliferate in response to IL-12 (Bloom and 
Horvath, 1994), indicating that IL-12 plays a key role in the regulation of cell- 
mediated cytotoxicity. McKnight et al (1994) investigated the effects of IL-12 in 
vivo using a hapten-protein conjugate as an immunising system. They found that 
systemic IL-12 strongly inhibits the development of IL-4-producing T cells. It also 
promotes the production of IFN-y by antigen-responsive T cells. They concluded 
that, in vivo, IL-12 blocks the development of Th2 cells and stimulates 
differentiation towards the Thl pathway. This may be as a result of direct effects 
on activated T cells or from stimulation of NK cells leading to increased secretion 
of IFN-y.
1.9 Thl to Th2 Switching
While the Th cell phenotype appears stable after differentiation in normal 
conditions, various experimental systems have demonstrated that, by adding or 
blocking the cytokines necessary for differentiation, Th cell phenotype can be 
altered. IL-10 inhibits antigen-stimulated proliferation by Thl clones (Fiorentino
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et al, 1989), while Tli2 clones cultured in the presence of IL-12 produce increased 
IFN-y and reduced IL-4, in keeping with a Thl phenotype. When Thl cell lines are 
cultured in the presence of anti-IL-12 antibodies during antigenic stimulation, they 
produce elevated levels of IL-4 (Manetti et al, 1993).
The direction of the immune response in vitro can therefore be altered by 
either blocking or adding the key regulatory mediators of differentiation at antigen 
presentation. The question has, therefore, been asked as to whether this is possible 
in an in vivo setting and whether this would alter inimune-mediated disease 
processes such as allograft rejection.
1.10 Effects of Interleukin-12 in vivo
As IL-12 has been demonstrated to play a central role in the 
differentiation of T-helper cells and in vitro work has suggested that neutralising 
the effects of IL-12 on immunocompetent cells can encourage the generation of a 
Th2 phenotype, considerable attention has focused on the role of IL-12 in animal 
models of disease.
1.10.1 Parasitic Infection
In the context of the Thl/Th2 paradigm, one of the most closely studied 
models has been that of parasite infection in mice. Studies have demonstrated that 
the ability of a host to eradicate an invading organism effectively depends on the 
type of specific immune response generated and this is influenced by the genetic 
control of the host. Leislimania major is an intracellular protozoan parasite which 
evokes different responses in different strains of mice. C57B1/6 mice respond to
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Leislimania major infection with a strong Thl response, characterised by strong
DTH. Antibody levels aie low, with no elevation of IgE. There are high levels of
IFN-y and low levels of IL-4 expression. This results in a localised infection
.which is ultimately cleared by the host. In marked contrast, Balh/c mice produce a
strong Th2 response with high antibody levels. High levels of IL-4 production are
.seen and IFN-y expression is low and there is no DTH response. This leads to a
severe and progressive generalised disease which ultimately proves fatal (Heinzel 
etal, 1991).
IFN-y appears to be required for the generation of a protective Thl
response and a single injection of anti-IFN-y monoclonal antibody to neutralise
endogenous IFN-y converts a normally resistant mouse into a susceptible mouse
which develops the generalised disease (Scott et al, 1989). In addition, treatment
with recombinant IL-12 provides protection to normally susceptible mice infected
with Leislimania. In contrast, treatment of resistant C57B1/6 mice with a
neutralising IL-12 antibody abolishes their protective immunity and exacerbates
the infection. This is associated with a decrease in Thl cytokine production by
.lymphocytes re-stimulated in vitro with specific antigen, suggesting an abrogation 
of the Thl response (Sypek et al, 1993). Protection against Leishmania major 
infection is dependent on the production of IL-12 by macrophages (Doherty and 
Coffman, 1999). To confirm that these results are directly attributable to Thl and 
Th2 phenomena, Thl and Th2 cell lines have been prepared which are specific for 
Leislimania antigens. When these cells are injected back into infected mice, the 
Thl line completely cures the infection while the Th2 line exacerbates the course 
of the disease (Scott et al, 1988).
.
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The relative contribution of Thl and Th2 cells to the immune response 
against other infective agents has also been examined. Listeria monocytogenes is a 
facultative intracellular bacterium and production of IFN-y is required to clear the 
infection in mice. Immunocompetent CB-17 mice usually clear Listeria infection 
by the generation of Thl cells. However, when animals are treated with polyclonal 
anti-IL-12 antibodies mice are rendered more susceptible to infection and die in 
response to a normally sublethal dose of Listeria (Tripp et al, 1994). These 
findings suggest that IL-12 is necessary for the generation of an effective Thl 
response, and when this is blocked, the disease process is radically altered.
Trypanosoma cruzi is another intracellular parasite in which a Thl 
response is protective, while a Th2 response leads to disease progression. 
Susceptible mice can, however, be rendered immunocompetent by injection of 
Thl cells specific for the antigen (Nickell et al, 1993).
Th2 responses are required to deal adequately with other infectious 
agents such as the multicellular helminths. Trichuris muris infection induces a Th2 
response in resistant mice. In susceptible strains, however, a Thl response is 
generated and they fail to clear the infection. When susceptible mice are pre­
treated with neutralising IFN-y antibody, they develop resistance. Similarly, when 
they are treated with IL-4 they also clear the infection whilst, when animals are 
pre-treated with neutralising IL-4 antibody, the condition is exacerbated (Else et 
al, 1994). With another helminth, Nippostrongylus brasiliensis, a Th2 response is 
generated by immunocompetent Balb/c mice with stimulation of IL-3, IL-4, IL-5 
and IL-9 production which induces IgE, eosinophil and mast cell responses and 
results in clearance of the infection. Treatment of animals with IL-12 reduces
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therefore, questioned whether this would be possible in other immune-mediated 
diseases, and, as IL-12 has been demonstrated to play a definitive role in the
1.10.2 Experimental Colitis
Neurath et al (1995) described a murine model of chronic intestinal 
inflammation induced by colonic installation of the chemical hapten 2,4,6- 
trinitrobenzene. This leads to the development of chronic, transmural colitis with
the disease leads to a striking improvement in the clinical and histological picture
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protection, with increased egg production by parasites and suppression of adult 
worm expulsion. IL-12 also inliibits IgE production and eosinophil activity as well Îas the generation of the Th2 cytokines (Finkelmann et al, 1994).Thus treatment with IL-12 can inliibit the production o f Th2 cytokines
and stimulate Thl cytokine production in vivo, even for antigens which would
,normally evoke Tli2 responses. It is therefore possible, in models of murine 
infection, to polarise the immune system in a specific direction by exposing the
early immune response to key immunoregulatory cytokines. Other workers have, Î
generation of T-helper responses, work has concentrated on using neutralising IL-
12 antibodies to block IL-12 effects in a variety of models.
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weight loss and diarrhoea. The disease observed is similar to that of Crohn’s
+disease in humans. The inflamed murine colon contains a heavy CD4 T cell
infiltrate. When infiltrating cells are isolated and re-stimulated in vitro, they
produce increased IFN-y and IL-2 and decreased IL-4 when compared to cells
from untreated controls, indicating that this is a Thl type disease. Neutralising
.endogenous IL-12 by administration of a monoclonal anti-IL-12 antibody during
and is often curative. In addition, T cells from colitic animals treated with anti-IL- 
1 2  antibody do not produce IFN-y when re-stimulated in vitro, indicating that by 
neutralising IL-12 one can abrogate the Th-1 response and significantly alter 
clinical outcome.
1.10.3 Contact Hypersensitivity
Contact hypersensitivity is a delayed type immune reaction which, in 
mice, is mediated by a Thl type response. When a hapten reagent which induces 
contact hypersensitivity is applied to the skin, mRNA for IL-12 is increased in 
regional lymph nodes. However, when mice are pre-treated with monoclonal anti- 
IL-12 antibody prior to sensitisation there is suppression of the clinical 
hypersensitivity reaction in a dose-dependent manner. Injection of anti-IL-12 
antibody into pre-sensitised mice significantly suppresses the hypersensitivity 
reaction, indicating that by neutralising IL-12, both the induction of the Thl 
response and the effector phase of the response can be abolished (Riemann et al, 
1996).
1.10.4 Experimental Allergic Encephalomyelitis
Experimental allergic encephalomyelitis (EAE) is an inflammatory 
autoimmune disease of the central nervous system and has been widely used as an 
animal model for multiple sclerosis. The experimental disease is characterised by 
the onset of a progressive paralysis which usually recovers spontaneously. 
Histologically, there is perivascular infiltration of the CNS by mononuclear cells. 
The disease can be induced in a number of animal species by immunisation with
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myelin basic protein (MBP) or proteolipid protein (PL?) or by the adoptive 
transfer of MBP or PLP-sensitised CD4"  ^T cells (Liblau et al, 1995). EAE appears 
to be a Thl mediated disease: the inflammatory lesions seen in the CNS ai*e 
similar to a DTH reaction, and immunohistochemical studies of CNS lesions 
reveal the presence of IL-2, TNF and IFN-y, but little IL-4 in lesions during the 
acute disease. However, during the recovery phase, IFN-y is low or undetectable 
while IL-4, IL-10 and TGF-P are elevated. In mice injected with CD4^ T cells 
which have been stimulated in vitro with PEP in the presence of IL-12, the 
resulting disease is more severe and prolonged. Interestingly, when mice are 
treated with a polyclonal neutralising IL-12 antibody injected intraperitoneally 
after CD4^ T cell transfer, paralysis is, to a large extent, prevented, with only 40% 
of animals developing mild symptoms of the disease. IL-12 therefore plays a 
pivotal role in the development of EAE and, by neutralising endogenous IL-12, 
the disease can be prevented and the Thl response abolished (Leonard et al, 1995, 
Gately et al, 1998).
1.10.5 Graft versus Host Disease
Several studies have analysed the relative contribution of Thl and Th2 
responses to the development of graft versus host disease (GVFID) in murine 
models (Via et al, 1994, Williamson et al, 1996). The injection of DBA/2 spleen 
cells into immunocompetent (C57B1/6 x DBA/2) Fi mice (BDFi) induces a 
clironic GVHD in which the donor CD4^ T cells become activated and produce 
Th2 type cytokines which stimulate autoreactive B cells to differentiate into 
antibody secreting cells. Serum Ig levels of all isotypes, including IgE are
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.increased. Conversely, CTL function is reduced and donor antihost CTL activity is 
barely detectable. An autoimmune disease resembling human systemic lupus 
eiytlnomatosis develops in this strain combination. In marked contrast, injection 
of C57B1/6 spleen cells into BDF; strain mice results in an acute GVHD in which 
donor CTLs become activated and cause the death of the host by destruction of the 
host immune and haemopoetic systems. The acute disease is associated with 
increased IFN-y production (Via et al, 1994). In the chronic GVHD model, when 
BDFi mice are treated with IL-12 at the time of DBA/2 cell transfer, mice develop
::5;
an acute rather than clnonic GVHD. Specifically, treatment with IL-12 blocks 
autoantibody production, induces antihost CTL activity and leads to the 
elimination of most host T and B lymphocytes. However, when mice with 
established clmonic GVHD are treated with IL-12, there is no decrease in 
autoantibody responses and there is no induction of anti-host CTL suggesting that 
treatment with IL-12 may be most effective if given early during the immune 
response.
In the same experimental model, when mice are pre-treated with 
neutralising IL-12 antibody, C57B1/6 spleen cell injection fails to provoke the 
acute form of GVHD (Williamson et al, 1996). Associated with this is reduced 
production of IFN-y with increased production of IL-10, indicating that, by 
blocking the effects of IL-12 in vivo, an anticipated Thl response can be polarised 
to a Th2 response and this can alter the clinical disease.
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ï1.11 Interleukm-12 in Transplantation
In view of the central role of IL-12 in the differentiation and maintenance
.of Thl cells and its ability to inliibit the development of Th2 cells, IL-12 is an
obvious choice as a target molecule for attempts to manipulate the rejection
'response.
Gorczynski et al (1996, b) assessed the effect of a neutralising IL-12 
antibody on skin graft smwival in a minor mismatch model as described earlier.
Portal vein injection of donor strain cells prolongs skin graft survival in this 
murine model. Skin graft survival is further prolonged when graft recipients are 
treated with both a neutralising anti-IL-12 antibody plus portal vein injection of 
donor strain cells. When cells from such treated animals are re-stimulated in vitro 
with donor antigen Th2 cytokine production is enhanced compared to that by cells 
from unmodified graft recipients and from those treated with portal vein injection 
of donor strain cells alone. Furthermore, treatment with a combination of anti-IL- 
12 antibody plus recombinant IL-13 (a Tli2 cytokine) further prolongs graft 
survival.
Conversely, in a mouse cardiac allograft model, treatment with anti-IL-12
antibody actually increased allograft rejection (Piccotti et al, 1996). Unmodified
.rejection in this model is characterised by a Thl response within the graft, while 
treatment with anti-IL-12 induces some Th2 cytokine expression with entranced 
expression of IL-4 and IL-10, but not IL-5 mRNA within the graft. However, IFN- 
Y production is not inliibited by antagonism of IL-12. This failure of blockade of 
endogenous IL-12 to prevent allograft rejection has been further investigated 
(Piccotti et al, 1997, b). The Thl cells generated by alloantigen exposure in the
I
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presence of an IL-12 antagonist are predominantly CD8  ^ T cells. Interestingly, 
prolonged cardiac allograft survival is observed when mice are treated with a 
combination of IL-12 (p40)2, an IL-12 antagonist, and in vivo depletion of CD8  ^T 
cells, although neither of these treatments alone prolong allograft survival. The 
authors suggested that blockade of endogenous IL-12 alone may not be sufficient 
to prevent Th cells from differentiating into Thl cells. However, when the 
generation of Thl cells is prevented, allograft survival may be prolonged. 
Treatment of mice with recombinant IL-12 significantly increases the Thl 
response generated to an allogeneic heart graft (Piccotti et al, 1999), with 
increased levels of IFN-y produced by cells from treated animals when they are re­
stimulated in vitro. Interestingly, however, this up-regulated Th-1 response is not 
associated with accelerated graft rejection, as grafts are rejected at the same time 
as untreated controls.
Li et al (1998) demonstrated that treatment with anti-IL-12 antibody 
injected intra-peritoneally ai'ound the time of allogeneic pancreatic islet grafting in 
a mouse model is able to polarise the normal Thl rejection response to a Th2 
response, with high expression of IL-4 and IL-10 within the grafts. Thus, by 
neutralising endogenous IL-12, a Thl to Th2 shift is produced. Interestingly, this 
Th2 shift was not associated with prolonged graft survival in MFIC-mismatched 
strain combinations, but was associated with increased graft survival in minor 
antigen mismatch combinations.
Controversy does, therefore exist as to the relevance of the Thl/Th2 
paradigm in transplantation. While there is strong evidence that unmodified 
rejection is associated with a Thl response, there is conflicting evidence as to
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Till / Th2 paradigm in transplantation. Endogenous IL-12 was neutralised using a
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whether tolerance is associated with a Th2 response. In experimental models 
where the cytokine response has been manipulated, rejection can certainly still 
occur in the presence of a Th2 response (e.g. Chan et al, 1995, Piccotti et al,
1996). Fiurther work is, therefore, required to analyse the cytokine responses in
■
transplantation to determine the role of Th2 activation in tolerance.
1.12 Aims of This Study
Interleukin-12 is a key immunoregulatory cytokine involved in the 
regulation of Thl/Th2 balance both in vitro and in vivo. It promotes a Thl
response by inducing IFN-y production by both Thl cells and NK cells and by
directly stimulating Thl cells. In addition, it has inhibitory effects on Th2
responses. IL-12 is also able to direct the polarisation of the immune response
away from an anticipated Th2 response to that of a Thl response in certain 
experimental models and this can have profound effects on the progression of 
pathological conditions. In addition, by neutralising endogenous IL-12, an 
anticipated Thl response can be abrogated, and a Th2 response generated instead. 
Thl responses initiate allograft rejection by promoting both CTL and DTH 
responses which serve as the final effector mechanisms by which allograft 
rejection occurs. IL-12 is, therefore, a suitable target molecule in experiments 
investigating allograft rejection and the generation of tolerance.
The central aim of this study was to investigate the role of IL-12 in the
rejection of allogeneic tissue, and, in particular, to determine the relevance of the
polyclonal anti-IL-12 antibody in a mouse host which was then transplanted with
■--fi
allogeneic tail skin and graft survival assessed. This experimental model was used 
to determine whether anti-IL-12 antibody could effect a switch from the normal 
Th-1 driven rejection response to a potentially less harmful Th-2 response, and 
whether this would equate with prolonged graft survival.
The immune response in both control and treated animals was analysed to 
determine the mechanisms involved. This was done using a variety of in vitro 
techniques including mixed lymphocyte reactions, cytokine analysis by ELISA
.
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and cytotoxicity assays.
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Cytokine Mol. Wt. 
(UD)
Source Target cell Receptor
IL - la 17 macrophages T and B cells, 
macrophages
immunoglobulin
superfamily
IL-1(3 17 epithelial cells T and B cells, 
macrophages
immunoglobulin
superfamily
IL-2 15.5 T cells T and B cells, 
NK cells
haemopoietin 
receptor family 
common y chain
IL-3 20-32 T cells mast cells, 
macrophages, 
basophils & 
eosinophils
haemopoietin 
receptor family 
common |3 chain
IL-4 18-20 T cells, basophils 
& mast cells
T and B cells, 
mast cells & 
monocytes
haemopoietin 
receptor family 
common y chain
IL-5 12
24 dimer
T cells 
mast cells
eosinophils, 
basophils & B 
cells
haemopoietin 
receptor family 
common P chain
IL-6 21-26 macrophages, 
fibroblasts, T 
cells & mast 
cells
T and B cells, 
hepatocytes & 
osteoclasts
haemopoietin 
receptor family 
gp 130
IL-7 25 stromal cells T and B cells, 
monocytes
haemopoietin 
receptor family 
common y chain
IL-8 8-10 monocytes, 
macrophages, 
T cells, 
fibroblasts, 
neutrophils, 
endothelial & 
NK cells
T and B cells, 
neutrophils, 
basophils, 
monocytes and 
endothelial cells
chemokine 
receptor family
IL-9 14 T cells T cells, 
macrophages
haemopoietin 
receptor family 
common y chain
IL-10 17-21 T cells, 
monocytes
T and B cells, 
mast cells
IL-12 p35
p40
B cells, 
monocytes, 
macrophages
T cells, 
NK cells
haemopoietin 
receptor family 
gp 130
IL-13 9-17 T cells monocytes, 
macrophages and 
B cells
haemopoietin 
receptor family 
common y chain
IL-14 50-60 T and B cells B cells
11-15 14-15 monocytes, 
epithelial cells
T cells, LAK 
cells
haemopoietin 
receptor family 
common y chain
IFN-Y 20-25 T cells, NK cells many cell types IFN-y receptor
Figure 1.1: a summary of some o f the different cytokines which play a role in T ceil function.
ThO
IL-4IFN-y, IL-12
IL-4 Th2Thl inhibition
IF N -yI
IL-2, IFN-y 
TNF-p
I
IL-4, IL-5, IL-6, 
IL-10, IL-13
Humoral immunityCell-mediated immunity
Figure 1.2: Differentiation of CD4 T cells. T helper cell subsets differentiate from a common 
undifferentiated precursor ThO cell, the differentiation being influenced by the cytokines present 
at the time of antigen presentation. IL-12 promotes differentiation into Thl cells whereas 
IL-4 promotes differentiation into Th2 cells.
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CHAPTER 2 
MATERIALS AND METHODS
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2.1 Animals
Skin graft survival was assessed in various in-bred strains of mice. 
C57B1/6 (H2'^) and DBA/2 (H2^) mice were used as recipients of tail skin grafts 
from semi-allogeneic (C57B1/6 x DBA/2) Fi (BDFi) donors (H2^^). These mouse 
strain combinations were chosen because, in previous studies, treatment with IL- 
12 and anti-IL-12 antibody has been shown to polarise the GVH alloimmune 
responses to Thl and Th2 responses respectively (Williamson et al, 1996). In 
some experiments, fully allogeneic skin grafts were performed between the two 
parental strains.
Animals were housed in the Central Research Facility of the University of 
Glasgow and were given food and water ad libitum.
2.2 Skin Grafting
Mice aged between 6  and 10 weeks were used for skin grafting 
experiments. Tail skin grafts were carried out using a modification of the method 
described by Billingham and Madawar (1951). Donor animals were sacrificed by 
cervical dislocation and their tail skin removed and cut into pieces approximately 
1cm. by V2 cm. Recipient animals were anaesthetised using halothane and oxygen 
inhalation supplied thiough a nose cone from a vaporiser in a standard anaesthetic 
machine. The thorax was shaved with clippers and the recipient site on the left 
hemithorax prepared using an operating microscope. Thin slivers of full thiclcness 
trunk skin were removed to form the edges of a square slightly larger than the tail 
skin graft and the central portion of the square then gently removed, taking care 
not to damage the fine, vascularised layer of the paniiiculus carnosiis which acted
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as the graft bed and from which recipient blood vessels grew into the graft to give 
it a blood supply. This layer could be clearly visualised with the operating 
microscope. The graft was then laid onto the recipient site and held in place using 
“spot welds” of Histoacryl tissue glue (Braun, Germany) to attach each corner of 
the graft to the recipient skin edge.
A small square of paraffin gauze dressing (Smith and Nephew, U.K.) was 
then placed over the graft and a circumferential bandage of sleek Avrapped around 
the thorax of the recipient, talcing care not to cause respiratory impairment. 
Animals were allowed to recover from the anaesthetic under close observation and 
were then housed individually to prevent disruption of the bandages or the grafts. 
Bandages were removed 7 days after grafting and the following day scoring of 
grafts was started.
2.2.1 Assessment of Skin Graft Survival
Skin grafts which had not been accepted when the bandages were removed 
were classed as technical failures and discounted. Grafts were assessed daily and
given a score of 1 to 4 with 4 being a healthy, well vascularised graft with no
■reduction in the original size of the skin graft, 3 being a decrease in size of the
graft of up to 20%, 2 being a reduction in size of up to 50% and 1 being loss of 
greater than 80 % of the grafted tissue. A score of 1 was taken as the point at
which rejection was deemed to have occurred (Azuma et al, 1989).
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2.3 In Vivo Neutralisation of Interleukin-12
Mice were treated with a polyclonal goat anti-mouse IL-12 IgG antibody. 
This was a generous gift from Dr. M. Gately (Hoffman-La Roche, New Jersey, 
U.S.A.). Animals were treated with the anti-IL-12 antibody (0.5 mg. in 0.2 mis. of 
phosphate-buffered saline (PBS)) i.p. on days -1 ,2 ,5  and 8 with grafting on day 0. 
Additional animals were treated with a combination of anti-IL-12 antibody and 
donor-specific spleen cells (see below). These mice were treated with the anti-IL- 
12 antibody either on days -1, 2, 5 and day 8 with donor spleen cell injection on 
day -7 or on days -8,-5, -2 and day 1 again with spleen cell injection on day -7.
Preparation of the antibody used in this study has been described (Tripp et 
al, 1994). Briefly, a goat was immunised with 200pg of recombinant mouse IL-12 
in complete Freund’s adjuvant injected subcutaneously. This was boosted with 
further recombinant IL-12, lOOpg on day 28, 50 pg on day 42 and monthly 
injections of 10 pg of recombinant IL-12 thereafter. Serum was collected 
fortnightly beginning on day 42. The IgG fraction of the antiserum was purified by 
affinity clu'omatography on protein-G Sepharose. IgG-enriched fractions were 
pooled, dialysed overnight at 4°C against PBS and stored at -20°C. At 0.2 pg/ml, 
the antibody completely neutralised 200 pg of IL-12 (M. Gately, personal 
communication). In addition, 450 pg of the antibody brought about significant 
changes in the Listeria monocytogenes murine infection model (Tripp et al, 1994). 
Thus, 2 mg, the dose with which mice were treated in this study, represents a 
fourfold increase in a dose which was seen to produce biological effects in vivo.
As a negative control, purified goat IgG (Sigma, St. Louis, Missouri, 
U.S.A.) was injected ip. as 0.5 mg. in 0.2 mis. PBS at the same time points as anti- 
IL-12 antibody.
2.4 Donor Spleen Cell Treatment
Groups of mice were treated with donor-strain spleen cells injected 
intravenously (iv.) 7 days prior to skin grafting. Spleens were hai'vested from 
donor-strain animals and cells freed by gentle rubbing over a sterile stainless steel 
wire mesh. Cells were washed twice in wash medimn (see below) and then passed 
through a 100 pm nylon mesh to remove any cell clumps or debris. Cells were 
re suspended in RPMI-1640 medium plus 25 mM Hepes (both Life Teclmologies 
Ltd., Paisley, U.K.), counted and made up to a final concentration of 2.5 x 10  ^
cells per ml.
Recipient mice were gently warmed in a light box to dilate their tail veins 
and then 0.2 mis. of the cell suspension injected intravenously, giving a dose of 5 
X 1 0  ^cells per animal.
2.5 In vitro Assays
To investigate the immunological mechanisms associated with the 
allogeneic graft response, spleens were removed from grafted animals and 
splenocytes analysed in vitro. For this part of the study, C57B1/6 mice were used 
as graft recipients and BDFi mice as donors.
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2.5.1 Washing Medium
Cells were washed in Hanks Balanced Salt Solution (Life Technologies 
Ltd.) with 2 % fetal calf serum (PCS) (Sigma, St. Louis, Missouri, U.S.A.) and 
100 u/nil of penicillin and 100 pg/ml of streptomycin (both Life Technologies 
Ltd.).
2.5.2 Standard Medium
Cells were cultured in standard medium made up of RPMI-1640 
containing 5 x 10'  ^ M mercaptoethanol, 2mM L-glutamine, 100 u/ml penicillin 
and 100 pg/ml streptomycin (all Life Technologies Ltd.) with 5 % fetal calf serum 
(Sigma).
2.6 Mixed Lymphocyte Reaction
Spleens were removed from animals at various times after grafting and 
spleen cells used in mixed lymphocyte reactions to assess T cell proliferation in 
response to donor alloantigen. Single cell suspensions of spleen cells were 
obtained by passing spleens thi'ough a sterile fine wire mesh and then washing the 
cells 4 times in washing medium. Spleen cells were used as responders and were 
resuspended in standard medium at a final concentration of 2  x 1 0  ^cells/ml.
Stimulator cells were harvested from the spleens of BDFi mice, rubbed
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itlirough a wire mesh, washed 3 times and then resuspended in standard medium. 
Stimulator cells were irradiated with 2000R, counted and resuspended at a final 
concentration of 4 x 10  ^cells/ml in standard medium.
ÏI
Ceils were plated out in triplicate wells in 96 U-bottomed well sterile 
culture plates (Nunclon, Kamstrup, Denmark) with 2 x 10  ^ responder cells per 
well and 4 x 1 0  ^ stimulator cells per well, with a final volume of 2 0 0  pl/well. 
Negative controls with responder cells plus 100 pi of standard medium and 
positive controls with responder cells plus 1 0 0  pi of medium containing 1 0  pg/ml 
concanavalin-A (conA) (Life Technologies Ltd.) were also prepared. Cultures 
were incubated in a humidified atmosphere at 37“C in 5 % CO2 and harvested at 
various time points.
Eighteen hours prior to harvesting, plates were pulsed with 1 pCi/well of 
^H-thymidine, and then harvested using a Skatron semiautomatic cell harvester 
(Skatron Instruments, As, Norway). Filter papers were allowed to dry and then 
analysed on a Betaplate Beta scintillation counter (Wallac, Finland) and expressed 
as a mean of counts per minute.
2.7 Cytokine Assays
Supernatants from MLRs were analysed to determine the cytokines 
produced by responder cells when re-stimulated in vitro by donor antigen. 
Cultures were prepared as for MLRs and supernatants were harvested at various 
time points. After harvesting, supernatants were centrifuged at 1200 rpm to 
remove any cellular debris and then stored in aliquots at -70 °C until used for 
cytokine analysis.
For cytokine analysis, samples were thawed and the cytokine content 
quantified using sandwich ELIS As to detect IL-2, IL-4, IL-5, IL-10 and IFN-y. All 
analyses were performed using capture and detection monoclonal antibodies from
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10% FCS .
again in triplicate, and plates incubated at 37 for 3 hours. Plates were washed 4 
times and then biotinylated anti-cytokine detecting monoclonal antibody, diluted 
in PBS / 10 % FCS , added at the concentrations shown in table 2.1 and plates 
incubated for a further hour.
Plates were washed 6  times, extravidin-peroxidase 2 pg/ml (Sigma) in 
PBS/ 10 % FCS added and plates incubated for one hour. Thereafter, plates were 
washed 8 times and 100 pi of 3,3,5,5 tetramethylbenzidine (TMB) substrate 
(Kirkegaard and Perry Laboratories, Gaithersburg, Maryland, U.S.A.) added and 
the colour allowed to develop. The reaction was stopped with lOOpl of 0.2M 
H2SO4 per well, after colour changes had developed, and then plates read on a 
Dynatech MR 5000 ELISA plate reader using Biolinx software programme
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Pharmingen (San Diego, U.S.A.) and compared against known concentrations of
recombinant mouse cytokines used as standard concentrations (Pharmingen).
Flat bottomed microtitre plates (Immulon 4, Dynatech Laboratories,
Chantilly, Virginia, U.S.A.) were coated with capture antibody at the
concentrations shown in table 2.1 made up to 50 pi in a coating buffer of 0.1 M
NaHCOa at pH 8.2 and incubated overnight at 4 °C. Plates were washed twice
with phosphate-buffered saline (PBS) plus Tween 20 (0.05%) and then blocked
with 200 pi of PBS / 10 % FCS solution and incubated for one hour at 37 °C.
Plates were washed twice and then standards and samples added: 100 pi of
standard cytokine solution were added, in triplicate wells, starting at the
,concentration shown in table 2.2 and then diluted in doubling dilutions with PBS /
■
1
Undiluted culture supernatant, 100 pi of each test sample, was added,
(Dynatech Laboratories) for analysis of results. Plates were read at a wavelength 
o f 450 nm. Cytokine concentrations were calculated with reference to standard 
curves constructed using recombinant cytokines (Pharmingen). The results of 
triplicates of test samples were quantified and expressed as a mean.
2.8 Assays for Cytotoxicity
Spleen cells from treated animals were assessed for their ability to effect 
cell-mediated cytotoxicity of donor lymphoblasts and NK-susceptible target cells.
2.9 Specific Cell-Mediated Cytotoxicity
Specific host anti-donor CTL activity was quantified using chromium 
release cytotoxicity assays. Two different target cell types were used.
2.9.1 Preparation of Cells
The mouse mastocytoma cell line P815, which expresses H2^ was used as 
the allospecific target cell. Cells were maintained in vitro and used when required. 
In addition, DBA/2 conA blasts were also used as allospecific targets. Spleens 
were harvested from DBA/2 mice and a single cell suspension prepared as before. 
Cells were cultured for 72 hours in standard medium which had 10 % FCS and 5 
pg/ml conA added. The cultured cells were then harvested, washed and 
resuspended in standard medium without FCS. Target cells were then incubated 
for 1 houi' at 37°C with 50 pCi of ^ ^Cr per 2x10^ cells.
Spleen cells from experimental animals were used as responder cells to 
assess specific CTL activity. Spleens were removed from grafted animals and
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5single cell suspensions prepared as described before, with cells used at a final 
concentration of 1.3 x 10  ^cells/ml in standard medium.
2.9.2 Cytotoxic T Lymphocyte Assays
Responder cells were cultured in 96 well V-bottomed microtiter plates 
(Titertek, Flow Laboratories, Riclrmansworth, U.K.), with 75 pi of 1.3 x 10  ^
cells/ml. in each well and then in doubling dilutions for each sample. Triplicates 
of each sample were cultured. 75 pi of target cells at a concentration of 1.3 x 10 
cells/ml. were added to each well to achieve effector to target cell ratios of 1 0 0 :1 ,
50:1, 25:1, 12.5:1, 6.25:1 and 3.125:1 for each sample. Negative controls of target 
cells with no responders, plus positive controls of target cells with 75 pi of Triton 
X (Sigma) were also set up.
Culture plates were centifuged briefly (1000 rpm for 1 minute) and then 
incubated for 4 hours at 37 °C. Supernatants were harvested, taking care not to 
disturb the cell pellet at the bottom of the culture well. Samples were analysed for 
chromium release with a 1282 Compugamma Universal Gamma Counter 
(Wallac). The percentage cytotoxicity was calculated using the formula:
..% cytotoxicity = experimental release - spontaneous release x 1 0 0  
maximum release - spontaneous release
2.10 Natural Cytotoxicity
NK cell activity was measured in experimental animals using a chromiun
' Irelease cytotoxicity assay. YAC-1 cells were used as specific targets for NK cells 
(Williamson et al, 1996). YAC-1 cells were suspended in standard medium
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without FCS and incubated for 1 hour at 37 °C with 50 pCi of ^*Cr per 2 x 1 0 ^  
cells.
Effector cells were prepared from the spleens of treated animals as 
described before and resuspended in standard medium at a final concentration of
1.3 X 10  ^ cells/ml. 75 pi of effector cells were plated out onto microtiter plates in 
triplicate and then in doubling dilutions to give final effector to target cell ratios as 
before. YAC-1 target cells were added (75 pi of 1.3 x 10  ^ cells/ml) and the plates 
spun for 1 minute at 1000 rpm. Controls for maximum and spontaneous release 
were also prepared and plates were then incubated for 4 hours at 37 ®C. 
Supernatants were harvested and analysed and % cytotoxicity calculated as before.
2.11 Assays for Microchimerism
The persistence of injected donor cells in treated animals was assessed by 
flow cytometric fluorescence activated cell soiling (FACS) analysis. C57B1/6 
animals were injected with 5 x 1 0 ^  donor Fi splenocytes, and sacrificed 24 hours 
later. Other animals were treated with either 0.5 mg. anti-IL-12 ip. or 0.5 mg. goat 
IgG ip. 24 hours prior to spleen cell injection, and again animals were sacrificed 
24 and 72 hours after donor cell treatment.
Spleens and lymph nodes were removed from animals and single cell 
suspensions prepared. Cells were resuspended in PBS /2% FCS at a final 
concentration of 2 x 1 0 ^  cells/ml. 50 ml aliquots of each sample were incubated 
with antibody directed against donor MHC. Thus, 1 pi of biotinylated anti-H2D'^ 
(Pharmingen) was incubated with samples at 4 °C for 40 minutes in the dark to 
label any persisting BDFi cells (H2^ *^ ) in C57B1/6 recipients (FI2^). Positive
77
controls, labelling with 4 pi of biotinylated anti-H2D^ (Pharmingen) were also 
prepared. Further samples were incubated with anti-CD 3 antibody (Pharmingen) 
in order to differentiate the lymphocyte population from any red blood cells.
Following incubation with antibodies, samples were washed twice with 
PBS / 2% Bovine Serum Albumin (Sigma) and then 10 pi of Streptavidin R. 
Phycoerythrin (Sigma) or FITC (Vector Laboritories, Peterborough, UK) added to 
each tube and again incubated at 4 °C for 40 minutes. Samples were washed in 
PBS / BSA twice and then resuspended in PBS.
Analysis of samples was carried out using a Coulter Epics-XL flow 
cytometer (Hiahleah, Florida, U.S.A.).
'I'
2.12 Statistics
Survival of skin grafts in each of the experimental groups was compared 
using a Mann-Whitney U-test. This generated a p value for the comparison of 2 
groups and differences were deemed to be significant when p<0.05.
For in vitro assays, results were talceii as the mean of tlmee different 
experiments. The standard deviation of these results was calculated and results 
expressed as the mean +/- one standard deviation. Values for cytokine production 
in vitro by cells from treated animals were compared at the various time points.
Cytokine levels in the treatment groups were compared using the Wilcoxon 
matched pairs test and differences were taken to be significant when p<0.05.
1
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Table 2.1
Capture mAh 
pg/ml
Antibody
Isotype
(clone)
Detection mAb 
pg/ml
Antibody
isotype
(clone)
IL-2 2 IgG2a
(JES6-1A12)
1 IgG2b
(JES6-5H4)
IL-4 2 IgG2b
(BVD4-1D11)
1 IgGl
(BVD6-
2462)
IL-5 4 IgGl
(TRFK5)
4 IgG2a
(TRFK4)
IL-10 4 IgGl
(JES5-2A5)
2 IgM
(SXC-1)
IFN-y 2 IgGl
(R4-6A2)
1 IgGl
(XMG1.2)
Concentrations of capture and detection antibodies used in ELIS As. All were rat 
anti-mouse monoclonal antibodies and detection antibodies were all biotinylated. 
The cell clones used to produce the antibodies are shown in brackets.
Table 2.2
Cytokine Standard Samples
IL-2 200 u/ml
IL-4 200 u/ml
IL-5 200 u/ml
IL-10 40 ng/ml
IFN-y 200 u/ml
Concentrations of recombinant mouse cytokines used in ELISAs for the 
generation of standard curves.
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CHAPTER 3
EFFECTS OF ANTI-IL-12 ANTIBODY ON SKIN GRAFT SURVIVAL
80
3.1 Introduction
As already described, IL-12 is a key immunoregulatory cytokine, playing a
central role in the differentiation of ThO cells into committed Thl cells
(Trinchieri, 1995). The Thl response is associated with cell mediated immunity
and a DTH response, and this is characteristic of the response generated during
allograft rejection (Hall, 1991). Neutralising endogenous IL-12 has been shown to
.reduce or prevent the Thl response generated in GVH disease, and in other 
models of immune-mediated disease, and to have significant effects on the 
subsequent pathological process (Williamson et al, 1996, Gately et al, 1998).
The effect of neutralising endogenous IL-12 on allograft survival was, 
therefore, investigated. Allograft survival in a semi-allogeneic mouse skin graft 
model was assessed to determine whether antagonism of endogenous IL-12 would 
produce effects on allograft survival, and to determine whether this was associated 
with a down-regulated Thl response or the generation of a Th2 response.
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3.2 Effects of Anti-IL-12 Antibody Alone on Skin Graft Survival
Tail skin was taken from BDFi animals and grafted on to the thorax of 
either C57B1/6 or DBA/2 recipients as described in materials and methods. After 
removal of bandages, skin graft survival was assessed daily and rejection defined 
as loss of greater than 80% of the grafted tissue (Azuma et al, 1989). BDFi skin 
grafts were rejected rapidly by unmodified C57B1/6 recipients, with a mean 
survival time (MST) of 11.8 days (n= ll). BDFi donor skin grafted onto DBA/2
recipients was rejected less rapidly with a MST of 13.2 days (n=6). Syngeneic
grafts onto either parental strain survived indeftnitely (n=6). These results are 
shown in Fig. 3.1 and Fig. 3.2.
C57B1/6 and DBA/2 mice were treated with anti-IL-12 antibody prior to 
skin grafting to assess the effects of neutralising endogenous IL-12 on skin 
allograft survival. Mice were treated with 0.5 mg. of a goat anti-mouse IL-12 
polyclonal antibody on day -1, 2, 5 and 8 with grafting on day 0 (Figs 3.1 and 
3.2). There was no prolongation of graft survival in either of the groups treated 
with the neutralising antibody. Skin grafts in the C57B1/6 group had a MST of 
11.25 days (n=4) and those in the DBA/2 group had a MST of 12.8 days (n=5). 
When these results are compared statistically using the Mann-Whitney U test there 
is no significant difference between unmodified graft rejection and rejection in 
recipients treated with anti-IL-12 antibody in either strain combination. From 
these results, it can be concluded that treatment with a neutralising polyclonal 
anti-IL-12 antibody on its own is not sufficient to prolong allograft survival in this 
model.
3.3 Pre-treatment with Donor Spleen Cells
Donor-specific blood transfusion or donor antigen pre-treatment has been 
used extensively as a method for prolonging allograft survival in experimental 
models (e.g Takeuchi et al, 1992, Gorczynski et al, 1996, b, Wood and Morris, 
1995). This finding does have some clinical relevance as it has been observed that 
patients who received multiple blood transfusions prior to renal transplantation 
have greater graft survival rates compared to those who have not (Dossetor et al, 
1967, Chavers et al, 1997). In addition, it has been demonstrated that transfusion
:ï
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of patients with donor blood prior to renal transplantation increases allograft 
survival (Singal et al, 1985).
.In experimental murine models using minor MHC mismatched strains, 
intravenous injection of unaltered lymphoid cell populations leads to prolonged 
survival of allogeneic skin grafts (e.g. Heeg and Wagner, 1990). In this study mice 
were treated with 5 x 1 0 ^  donor-strain spleen cells injected intravenously 7 days 
prior to skin grafting. This method has been shown to prolong skin graft survival
in a minor mismatch model on a C57B1/6 background (Hori et al, 1992). Results
from pre-treatment of C57B1/6 mice with donor spleen cells prior to grafting with
BDFi skin are shown in Fig. 3.3. The MST of grafts was 9.9 days (n=9) and this is
not significantly different from unmodified graft recipients. Similarly, with
DBA/2 mice pre-treated with BDF; spleen cells and then grafted, MST was 11.2
days (n = ll) and again this is not significantly different from umnodified DBA/2
.graft recipients (Fig. 3.4). Thus, in this experimental model, pre-treatment with 
donor-specific antigen 7 days prior to grafting did not significantly alter graft 
rejection.
3.4 Timing of Donor Spleen Cell Pre-treatment
The timing of pre-treatment with donor antigen has been shown to be 
important in the outcome after transplantation (Wood and Morris, 1995). To 
investigate the lack of effect from donor cell pre-treatment 7 days prior to grafting, 
other C57B1/6 mice were pre-treated with 5 x 10  ^ BDFi cells injected
intravenously 4 days prior to grafting with BDFi tail skin. Allograft survival in
:
this group was 12.5 days (n=6) and this is not significantly different from graft
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survival in unmodified recipients or in the group pre-treated with donor cells 7 
days prior to grafting.
3.5 Combined Treatment with Anti-IL-12 Antibody and Donor-Specific 
Spleen Cells
Since neither treatment with anti-IL-12 antibody nor donor-specific spleen 
cells significantly altered skin allograft survival when given alone, mice were 
treated with a combination of the two therapies to determine whether they could 
prolong allograft survival together. Other workers have shown that combined 
treatment with donor alloantigen plus some other immunoregulatory therapy can 
prolong allograft survival. For example, murine heart grafts across a fully 
allogeneic mismatch survive indefinitely when mice are pre-treated with donor- 
specific transfusion plus anti-CD4 mAb (Bushell et al, 1995). In the model which 
they described, the timing of the donor antigen and the mAh therapy is critical for 
tolerance induction. Similarly, in a rat vascularised heart model, treatment with 
donor-specific transfusion plus intragraft continuous IL-4 therapy along with 
cyclosporin significantly prolongs graft survival (Levy and Alexander, 1995).
Mice of both C57B1/6 and DBA/2 strains were therefore treated with donor 
antigen in the form of 5 x 10  ^ BDFi spleen cells injected intravenously one week 
prior to skin grafting. Anti-IL-12 antibody was given as 0.5 mg. ip. on day -8, -5, - 
2 and 1 with skin grafting on day 0. These results are shown in Fig. 3.5 and 3.6. In 
the C57B1/6 group, skin graft survival was prolonged, with a MST of 17.0 days 
(n=9). These results, when compared with those for unmodified skin graft 
recipients, showed that this prolonged graft survival was statistically significant
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(Mann-Whitney U test, p<0.002). As a control for the anti-IL-12 antibody, 
C57B1/6 mice were treated with BDF] donor cells plus a purified goat IgG 
(Sigma). This was given, like the anti-IL-12 antibody, as 0.5 mg. on day -8, -5, -2 
and 1. Skin graft survival in this group was not prolonged with a MST of 11.8 
days (n=7). When compared statistically, this was not significantly different from 
allograft rejection in umnodified graft recipients, but was significantly reduced 
compared to treatment with donor spleen cells plus anti-IL-12 antibody (p<0.002).
DBA/2 mice treated with both BDF] spleen cells and anti-IL-12 antibody 
also showed prolonged skin graft survival, with the MST being 17.7 days (n=6). 
When compared with unmodified DBA/2 graft recipients, the treated group had 
significantly prolonged survival (p<0.002).
Thus treatment with a combination of anti-IL-12 antibody and donor 
spleen cells significantly prolongs skin graft survival in both of the parental 
strains.
3.6 Timing of Anti-IL-12 Antibody Treatment
Many other studies have demonstrated that the timing of potentially 
tolerising therapies is critical to their success (e.g. Pearson et al, 1992). The 
importance of the timing of anti-IL-12 antibody treatment, relative to donor 
splenocyte injection, was therefore assessed. C57B1/6 mice were given 5 x 10  ^
BDF] splenocytes iv. 7 days prior to grafting. They were then treated with 0.5 mg. 
anti-IL-12 antibody ip. on days -1, 2, 5 and 8, that is starting one week after the 
time which had already been shown to prolong allograft survival (Fig. 3.7). Mean 
survival time of grafts in animals treated with the later anti-IL-12 antibody
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injections was 13.8 days (n=6). When compared with graft survival in the group 
treated with donor cells plus the earlier anti-IL-12 antibody injections, there is a 
difference, with the earlier injection group surviving significantly longer than 
those given the anti-IL-12 antibody later (p<0.05). In addition, when graft survival 
in the group treated with donor cells plus later anti-IL-12 antibody injections is 
compared to that of umnodified graft recipients there is no significant difference, 
indicating that this treatment confers no benefit to allograft survival.
3.7 Treatment with Additional Donor Antigen
The effect of giving an additional injection of donor spleen cells was next 
investigated. Some workers have indicated that persistence of donor antigen may 
be important for allograft survival, and this may be one mechanism whereby 
donor-specific transfusion has its effect (e.g. Gorczynski et al, 1996, b, Bushell et 
al, 1995). Thus, giving an additional treatment of donor spleen cells during the 
pre-treatment protocol may be anticipated to have a beneficial effect on allograft 
survival.
C57B1/6 mice were pre-treated with the same regime which had been 
shown to significantly prolong allograff survival, namely 0.5 mg. anti-IL-12 
antibody on day -8, -5, -2 and 1 with 5 x 10  ^ BDFi spleen cells on day -7. In 
addition, mice were treated with a further iv. injection of donor spleen cells on the 
day of grafting, some 7 days after the first spleen cell injection. Results are shown 
in Fig. 3.8. Skin graft survival in this group was significantly prolonged compared 
to unmodified graft recipients, with a MST of 17.0 days (n=5, p<0.05). However,
this was exactly the same as in the group treated with a single injection of donor 
cells at day -7, plus anti-IL-12 antibody.
An additional treatment with donor-specific antigen on the day of grafting 
did not, therefore, significantly entrance graft survival compared to the group 
treated with a single spleen cell injection when both groups also received anti-IL- 
12 antibody.
iI3.8 Grafting Across a Fully Allogeneic Mismatch
Skin graft survival across a full MHC mismatch was also assessed by 
grafting skin from one parental strain onto the other parental strain (Figs. 3.9 and 
3.10). DBA/2 tail skin was grafted onto C57B1/6 recipients and the MST was 10.0 
days (n=10). When this was compared to BDFi tail skin grafted onto C57B1/6 
recipients (MST 11.8 days), there was no significant difference. When C57B1/6 
skin was grafted onto DBA/2 recipients the MST was 11.8 days (n=10) and this
i
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too was not significantly different from BDFi grafts to DBA/2 recipients (MST 
13.2 days).
The effect of antigen pre-treatment, either with or without anti-IL-12 
antibody was also assessed (Fig 3.11). C57B1/6 mice pre-treated with 5 x 10  ^
DBA/2 spleen cells 7 days prior to grafting were transplanted with DBA/2 skin 
grafts. The MST was 9.75 days (n=4) and this was not significantly different from 
unmodified graft recipients. Mice were also treated with donor specific spleen 
cells plus anti-IL-12 antibody on day -8, -5, -2 and 1 and graft survival assessed.
MST in this group was 11.8 days (n=5) and this also was not significantly 
different from unmodified graft recipients. This was, however, significantly
aa:
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reduced compared to the semi-allogeneic BDFi graft onto C57B1/6 animals pre­
treated with donor-specific spleen cells plus anti-IL-12 antibody (p<0.05). Thus 
pre-treatment with donor strain spleen cells plus anti-IL-12 antibody was not able 
to prolong fiilly allogeneic skin graft survival in this strain combination.
3.9 Discussion
As discussed earlier, Thl cells are the principal mediators of allograft 
rejection as they promote the cell mediated immune response, particularly CTL, 
and these serve as the terminal effector cell types in rejection (Hall, 1991). The 
hypothesis that polarisation of a Thl response to a Tli2 response may favour 
allograft survival has been suggested (Takeuchi et al, 1992, Dallman et al, 1991, 
Gorczynski et al, 1996, a). Reciprocal regulation of this response exists, whereby 
an up-regulated Tli2 response leads to a down-regulated Thl response (Mosmann 
and Sad, 1996). It may be anticipated, therefore, that, by preferential activation of 
an antigen-specific Th2 response, the destructive Thl response will be inhibited 
and allograft tolerance induced. Specific therapies which promote the polarisation 
of the immune system to a Th2 response are therefore being investigated for their 
role in allograft survival. IL-12, as a key regulator of the Thl response, is a 
suitable target molecule around which therapeutic strategies can be manipulated.
In the studies described here using a model of semi-allogeneic tail skin 
grafts in a murine host, neutralising endogenous IL-12 did not prolong allograft 
survival. There is a number of possibilities as to why neutralising endogenous IL- 
12 by itself failed. The amount of anti-IL-12 antibody used in this study may not 
have been sufficient to neutralise all endogenous IL-12. Against this, however, is
the fact that this same polyclonal goat anti-mouse IL-12 antibody has been used in 
another experimental mouse model and was effective at inhibiting a Thl response 
and generating a Th2 response (Tripp et al, 1994). In addition, the dose used here 
was 4 times that which was effective in these experiments. Furthermore, as 
discussed in later chapters, while anti-IL-12 antibody alone did not prolong 
allograft survival, it was effective in deviating the cytokine response away from 
Thl towards Th2. Thus, while it was not formally shown that all endogenous IL- 
12 was neutralised by this treatment, strong supportive evidence exists to suggest 
that it was.
Despite neutralisation of endogenous IL-12, skin allograft survival was not 
prolonged. These findings are in agreement with those of Piccotti et al (1996) who 
used the same polyclonal goat anti-mouse IL-12 antibody from Dr. M. Gately, as 
well as IL-12 p40 homo dimer in a murine vascularised cardiac allograft model. 
The IL-12 p40 homodimer is a soluble form of the p40 chain of IL-12 which 
competes with the cell surface IL-12 receptor, blocking the effects of IL-12. Thus 
they used 2 different methods for blocking the action of IL-12 in a heart allograft 
model, and found that iniribition of IL-12 around the time of grafting fails to 
prolong survival. In fact, neutralising IL-12 appears to cause a modest acceleration 
in rejection. Similarly, Li et al (1998) demonstrated that pre-treatment of 
recipients of pancreatic islet cell grafts with a neutralising anti-IL-12 antibody was 
unable to prolong allograft survival in full MHC-mismatch mouse models. 
Interestingly, however, such treatment was capable of prolonging graft survival in 
minor mismatch combinations. Thus neutralising endogenous IL-12 alone does 
not prolong allograft survival in MHC-mismatch strain combinations.
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Piccotti et al (1996) also investigated the effect of anti-IL-12 antibody on 
cytokine gene expression within the rejecting cardiac allografts and found that in 
unmodified mice, cardiac allograft rejection is characterised by a Thl response, 
demonstrated by detectable levels of IFN-y, with little expression of Th2 cytokine 
message. Conversely, in animals treated with anti-IL-12 antibody, IL-4 and IL-10 
expression is detectable, indicating an increase in Th2 cytokine message. IFN-y 
expression is not, however, inliibited. Thus, while treatment with anti-IL-12 
antibody induces Tli2 cytokine expression, it does not completely prevent the 
generation of Thl cytokines. Recently, IFN-y inducing factor (IGIF or also named 
IL-18) has been identified (Okamura et al, 1995, Okamura et ai, 1998). This 
cytokine augments NK cell activity and is produced by activated macrophages. 
IGIF may, therefore, mediate a second pathway for inducing IFN-y production by 
Thl cells (Okamura et al, 1998). Neutralising IL-12 alone may not, therefore, be 
sufficient to completely inhibit the generation of IFN-y in an allograft model as 
there appears to be some redundancy within cytokine pathways. Thus a pathway 
for Thl cytokine generation would still exist and this may be sufficient to effect 
allograft rejection.
The ability of IL-12 p40 knockout mice to reject an allograft has also been
studied (Piccotti et al, 1996). When grafted with a vascularised allogeneic heart,
IL-12 Icnockout mice reject their grafts at the same time as wild type animals
,treated with anti-IL-12 antibody, that is slightly earlier than unmodified controls.
In addition, lymphocytes taken from IL-12 Icnockout grafted mice and re­
stimulated in vitro with donor antigen are able to produce significant amounts of 
IFN-y, indicating that IL-12 is not required for the generation of Thl responses in
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an allograft model. Cytokine data from the work done in this study is presented 
and discussed in later chapters. Thus there appears to be considerable complexity 
within cytokine responses, and blocking one specific cytokine may not be 
effective in completely abrogating a specific T-helper cell response, as other 
pathways may be activated which ultimately stimulate the same effector cells.
In this study donor spleen cell injection was not sufficient to prolong 
allograft sui’vival in either semi- or fully allogeneic skin grafts. When donor- 
specific cells were given, no other form of immunomodulation was administered, 
and so host T cells, on encountering such antigen, would be able to react normally. 
In both C57B1/6 and DBA/2 recipients pre-treated with BDFi spleen cells and 
then skin grafted, rejection occurred more quickly than in the unmodified grafted 
groups (MST 9.9 days in C57B1/6 mice treated with spleen cells and 11.8 days in 
unmodified animals, and MST 11.2 days in DBA/2 mice pre-treated with donor 
cells compared to 13.2 days in unmodified graft recipients), although in neither 
strain combination were these differences statistically significant. It may be, 
therefore, that in this strain combination, pre-treatment with donor spleen cells 
alone only serves to sensitise the recipient and so make it reject the graft more 
quickly.
While the administration of donor antigen alone is, in certain experimental 
models, an effective strategy for the induction of peripheral tolerance to 
alloantigen, it does not result in tolerance in every situation. Indefinite survival of 
skin allografts is very difficult to achieve, as here. Other workers have, therefore 
sought to combine the benefits o f immunological specificity achieved by using 
donor antigen pre-treatment with low levels of less specific immunosuppressive
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therapies. For example, donor-specific transfusion plus cyclosporin treatment 
prolongs cardiac allograft survival in a rat model (Brunson et al, 1991), In the 
work of Wood’s group, donor-specific transfusion combined with anti-CD4 mAh 
results in antigen-specific peripheral tolerance. They observed that the anti-CD4 
mAb therapy induces short-term immunosuppression which is transient. If donor 
cells are given at the same time, however, while immunocompetence to other 
antigens recovers, as demonstrated by the ability to reject a third party heart graft, 
specific unresponsiveness to the donor antigen remains, and this results in
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peripheral tolerance to that alloantigen (Pearson et al, 1992). They have suggested 
that this specific unresponsiveness is due to the short-term persistence of donor- 
specific antigen in the host (Bushell et al, 1995).
In this study, combining 2 treatments, neither of which prolonged allograft
survival alone, produced significant prolongation of skin graft survival. This 
prolongation of skin graft survival was found when BDFi skin was transplanted 
onto either the C57B1/6 or DBA/2 parental strain when recipients were pre-treated 
with BDFi spleen cells plus anti-IL-12 antibody. Unlike the other combination 
methods described above, however, neither of these therapies are non-specifically 
immunosuppressive and therefore other mechanisms must be involved in the . i
prolongation of graft survival. i
Anti-IL-12 antibody has been shown to induce polarisation to a Th2 
response in a number of experimental models, including murine infections and 
graft versus host disease. However, in a murine vascularised cardiac allograft 
model, while expression of Th2 cytokines was up-regulated, allograft survival was 
not increased by treatment with anti-IL-12 antibody alone (Piccotti et al, 1996). As
discussed earlier, pre-treatment with donor cells may also polarise the immune 
response in a Th2 direction (Babcock and Alexander, 1996). It may be, therefore 
that these 2 therapies are additive and, when given together, they polarise the 
immune response more strongly in a Th2 direction, and this is sufficient to 
prolong allograft survival. Thus, treatment with one therapy alone may not be 
sufficient to polarise all alloreactive T cells to a Th2 response, while both given 
together are. This is supported by the findings of Gorczynski et al (1996, b) who 
found that when mice were treated with donor strain dendritic cells injected into 
the portal vein, allogeneic skin graft survival was prolonged. When 
immunocompetent cells were removed from such animals and re-stimulated in 
vitro, they produced reduced levels of Thl cytokines and increased levels of Th2 
cytokines. When mice were treated with portal vein injection of dendritic cells 
plus an anti-IL-12 antibody and recombinant IL-13, skin graft survival was further 
prolonged. Cells removed from these animals and re-stimulated in vitro produced 
even less of the Thl cytokines and even greater levels of IL-4 and IL-10 compared 
to those from animals given portal vein injections alone. Piccotti et al (1997, b) 
demonstrated that pre-treatment with a combination of IL-12 p40 homodimer, an 
IL-12 antagonist, plus a depleting anti-CD8 mAb in a mouse cardiac allograft 
model can significantly prolong allograft survival. Treatment with either the p40 
homodimer or anti-CD8 mAb alone does not prolong graft survival. They 
concluded that IL-12 antagonism inhibits the generation of CD4^ Thl cells. 
However, CD8  ^ T cells are unaffected and these cells alone are capable of 
inducing allograft rejection in this model. Inhibiting CD4^ Thl cells by IL-12 
antagonism, and depleting CD8^ T cells together is, however, sufficient to prolong
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heart graft survival. Thus there is evidence that different treatments can have 
additive effects on the polarisation of the allograft rejection response and this can 
increase allograft survival.
The finding that delaying anti-IL-12 antibody treatment in this model did 
not prolong skin graft survival is, however, at variance with this. When mice were 
treated with donor spleen cell injection on day -7 and anti-IL-12 antibody 
treatment delayed until day - 1 , 2 , 5  and 8 (with grafting on day 0), skin allograft 
survival was not significantly prolonged compared to that in umnodified graft 
recipients. If both treatments were additive and act by polarising the immune 
response in the Th2 direction, one would anticipate that survival would also be 
increased by late treatment with anti-IL-12 antibody. The potential exists, 
therefore, that polarisation of the immune response is not ultimately responsible 
for graft prolongation and that other mechanisms may be involved.
Allogeneic cells, when injected into full histocompatibility mismatched 
hosts ai'c rapidly eliminated. Sheng-Tanner and Miller (1992) demonstrated that 
injection of DBA/2 lymphoid cells into C57B1/6 recipient mice leads to rapid 
destruction of the donor cells. By labelling donor cells with FITC, the fate of such 
cells can be followed and it was found that at 3 days following injection, no donor 
cells can be detected within the circulating lymphocyte population. They 
concluded that the rapid elimination of fully allogeneic cells is due to NK cell 
killing because when NK cell activity is inhibited by treatment of recipient mice 
with antiasialo-GMl mAh in a C57B1/6 host, fully allogeneic Balb/c cells were 
detectable 3 days after injection. Interestingly, when they injected BDFi cells into 
C57B1/6 recipients they could still detect BDFi cells at day 3. It was also
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lymph node cells were injected after removal of red blood cells. It may be, 
therefore, that the differences which they observed are due to differences in the 
cell populations injected as in this study, a population of spleen cells, without 
removal of any red cells, were injected.
demonstrated that in this model, iv. injection of BDFi lymphoid cells leads to a 
prolongation of BDF i skin graft survival in DBA/2 recipients and that this was 
associated with donor cells persisting in the host for 3 days. They concluded that 
for donor cell injection to prolong allograft survival, donor cells must be able to 
survive within the host for at least 3 days. Sheng-Taimer and Miller also suggested 
that elimination of BDF] cells is also attributable to NK cell destruction. It was 
demonstrated that when recipient mice are treated with polymerised inosine 
cytidine, a procedure which boosts host NK cell activity (Djeu et al, 1979), BDFj 
donor cells camrot be detected at day 3 and skin graft survival is not prolonged.
These results are obviously at variance with the graft survival data 
presented in this study. Sheng-Taiuier and Miller found that BDF] cell infusion 
indefinitely prolonged BDFi tail skin survival in DBA/2 recipients. In this study, 
BDFi cell injection did not prolong allograft survival and, if anything, increased 
rejection rates. These differences are somewhat difficult to reconcile. In the 
experiments of Sheng-Tanner and Miller, however, donor cells were injected 4
days prior to grafting and, in addition, a combination of both spleen cells plus
i
In addition, in an attempt to investigate their results, C57B1/6 mice were 
injected with BDFi spleen cells 4 days prior to skin grafting and it was found that 
this did not prolong skin graft survival in this study. It must be assumed, therefore, 
that the cell population injected in the 2 different protocols was responsible for the
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differences in graft survival observed. Hori et al (1989) found that after injection 
of an unpurified donor-specific spleen cell population 7 days prior to grafting a 
MHC class II disparate skin graft in a mouse model, allograft survival is not 
prolonged. However, when the donor cell population is passed over Sephadex G- 
10 columns to remove APCs, skin graft survival is significantly prolonged. Thus, 
the nature of the cell populations injected can have significant effects on allograft 
survival, and this may explain the differences observed between this work and that 
of Sheng-Tanner and Miller.
Other groups have highlighted the significance of persistence of donor 
cells in the host for induction of tolerance. Bushell et al (1995) determined that 
tolerance to allogeneic heart grafts in mice is due to prolonged suiwival of donor
cells following anti-CD4 mAh therapy. When irradiated donor cells are injected,
:
tolerance does not follow. However, when repeated doses of irradiated cells are
given, tolerance ensues. They concluded that a single dose of irradiated cells does 
not remain within the host for sufficient time to generate donor-specific tolerance.
Persistence of donor cells may also be important in the model described in 
this work. There is some evidence to suggest that BDF] cells are eliminated by 
NK cells in C57B1/6 mice (Sheng-Tanner and Miller, 1994). By inhibiting NK 
cell-mediated destruction of donor cells, the ability of injected donor cells to 
increase allograft sui'vival may be enhanced. IL-12 is a potent activator of NK 
cells and was originally called NK cell stimulatory factor (Kobayashi et al, 1989). 
Blockade of endogenous IL-12 would, therefore, be expected to inhibit NK cell 
activity and possibly reduced NK cell killing of donor cells. This may allow
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persistence of donor antigenic cells for long enough to allow prolongation of 
allograft survival.
In this model, the effect of donor-specific spleen cell injection plus anti-IL- 
12 antibody may not, therefore, be related to polarisation of immune response to 
Th2, but may be a consequence of the inhibitory effect of anti-IL-12 antibody on 
NK cells, allowing persistence of donor antigen. These possibilities have been 
analysed using in vitro methods and the results are presented in the following 
chapters.
Interestingly, in a fully allogeneic mismatch, treatment with donor-specific 
cells plus anti-IL-12 antibody did not prolong allograft survival. This may be due 
to the rapid destruction of donor cells by NK cells despite anti-IL-12 antibody 
treatment. Thus blocking of endogenous IL-12 activity may not be sufficient to 
prevent NK cell killing across a fully allogeneic mismatch. Similar results were 
found by Li et al (1998) in a murine pancreatic islet allograft model. They found 
that pre-treatment of graft recipients with anti-IL-12 antibody was able to induce a 
Th-1 to Th-2 shift within the graft but that this was not associated with prolonged 
allograft survival in a full MHC-mismatch model. However, such treatment in 
minor mismatch models, again inducing a Thl to Th2 shift, was associated with 
prolonged allograft survival.
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3.10 Summary of Results of Chapter 3
1. Pre-treatment of recipient mice with either a neutralising anti-IL-12 
antibody or an intravenous injection of donor-strain spleen cells alone does not 
prolong skin graft siu'vival in this semi-allogeneic mismatch model.
2. Pre-treatment of recipient mice with a combination of anti-IL-12 
antibody and donor strain spleen cells does significantly prolong skin graft 
survival in this model.
3. The timing of treatment with anti-IL-12 antibody relative to donor 
spleen cell injection was important. Pre-treatment of mice with anti-IL-12 
antibody on day -8, -5, -2 and 1 and donor spleen cell injection on day -7 
prolonged skin graft survival, while delaying treatment with the anti-IL-12 
antibody did not prolong graft survival.
4. Giving an additional donor spleen cell injection on the day of grafting 
after pre-treatment with anti-IL-12 antibody and donor spleen cell injection as 
before did not further increase skin graft survival.
5. Pre-treatment with a combination of anti-IL-12 antibody and donor 
spleen cell injection did not prolong skin graft survival in a fully allogeneic 
mismatch.
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Figure 3.1 Sidn graft survival after treatment with anti-IL-12 antibody. C57B1/6 
mice were grafted with tail skin from either BDFi donors (BDFi-Bl/6) or syngeneic 
animals (B1/6-B1/6). One group was treated with 0.5mg anti-IL-12 antibody on days -1, 
2, 5 and 8 with grafting of BDFi skin on day 0 (BDFi-Bl/6 + aIL~12).
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Figure 3,2 Skin graft survial in DBA/2 mice treated with anti-IL-12 antibody.
DBA/2 mice were treated with anti-IL-12 antibody as in Figure 3.1.
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Figure 3.3 Survival of sldn grafts on Bl/6 recipients after treatment with donor 
antigen. Mice were injected with 5 x 1 0  BDFj splenocytes 7 days prior to skin 
grafting with BDFj skin (BDFi-Bl/6 + donor cells).
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Figure 3.4 Suiwival of skin grafts on DBA/2 recipients after treatment with 
donor antigen. DBA/2 mice were treated as above.
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Figure 3.5 Skin graft survival in C57B1/6 mice treated with a combination of donor 
antigen plus anti-IL-12 antibody. Mice were treated with donor spleen cells 7 days 
prior to grafting plus 0.5 mg. anti-IL-12 antibody on day -8, -5, -2 and 1 (BDFi-Bl/6 + 
donor cells + aIL-12). Another group was treated with pui’ified goat IgG plus donor 
spleen cells as a negative control (BDFi-BI/6 + donor cells + goat IgG).
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Figure 3.6 Skin graft survival in DBA/2 mice treated with both donor antigen 
plus anti-IL-12 antibody. The treatment regime was identical to that in Figure 3.5.
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Figure 3.7 Timing of treatment with anti-IL-12 antibody. C57B1/6 mice were grafted 
with BDFi skin after treatment with donor spleen cells on day -7 as before, plus 
anti-IL-12 antibody. This was given as the same dose as before, but either on days -8,
-5, -2 and 1 or on days-1 ,2 ,5  and 8 (late group).
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Figure 3.8 Additional treatment with donor cells. C57B1/6 mice were grafted with 
BDFi tail skin and one group also treated with donor cells and anti-IL-12 antibody 
as before. A third gi'oup was given donor cells on day -7 and anti-IL-12 antibody plus 
a further injection of donor spleen cells on day 0 (donor cells d-7 & 0).
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Figures 3.9 and 3.10 Survival of fully allogeneic sldn grafts. C57B1/6 mice 
were grafted with DBA/2 tail skin and vice versa. Results are compared with 
grafting of BDF i skin.
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Figure 3.11 Survival of fully allogeneic grafts after treatment of recipients.
C57B1/6 mice were treated in the same manner as for assessment o f semi-allogeneic 
graft survial.
CHAPTER 4
PROLIFERATION AND CYTOKINE PRODUCTION IN VITRO
I
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4.1 Introduction
In order to analyse the immune mechanisms underlying prolonged graft 
survival compared to unmodified graft rejection, spleen cell cultures were prepared 
from C57B1/6 mice which had received BDFi skin grafts. Cells from animals in the 
different treatment regimes were used in a variety of in vitro experiments.
In a mixed lymphocyte reaction (MLR), single cell suspensions of responder 
T cells are cultured with allogeneic stimulator lymphocytes. The activating stimulus 
is the foreign histocompatibility antigens on the stimulator cells and, in mice, both 
CDd"  ^ and CDS’*” T cells will proliferate, although CD4^ T cells will proliferate to a 
greater extent (Kitagawa et al, 1991). For such proliferation to occur, a source of 
APCs is also required. In addition to producing a measure of proliferative responses 
to alloantigen, MLRs are also useful for the assessment of cytokine production by the 
proliferating responder cells. For this, supernatants can be harvested from cultures 
and analysed for specific cytokines.
from BDF] mice, irradiated with 20 Gy and added at a concentration of 4 x 10^
1 pCi per well, was added. After a further 18 hours, cultures were analysed using 
incorporation of thymidine as a measure of proliferation.
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4.1 Determination of Optimal Conditions for MLR
Spleens were removed from C57B1/6 mice which had received no therapeutic 
intervention or else had received a BDF] skin graft 3 days previously, and a single 
cell suspension prepared as described earlier. Cells were cultured in 96 well culture 
plates at a concentration of 2 x 10 cells/ml. Stimulator spleen cells were removed
:
I
cells/ml. Cultures were maintained for different lengths of time before H-thymidine,
f
Ii
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With cells taken from naive, ungrafted animals, there were moderate levels of
.proliferation at the 5 time points assessed, namely 24, 48, 72, 96 and 120 hours in
vitro. These results aie shown in figure 4.1. With cells taken from animals which had
been sensitised to donor antigen by means of a skin graft, proliferation was more
pronounced. The counts obtained from these groups were compared with the counts
obtained from wells containing responder cells from animals which had received a
.skin graft with no stimulators added and which thus acted as a negative control. At 
24 hours, proliferation in the group which had received a skin graft was slightly 
greater than in the naive group and this in turn was slightly greater than in the 
unstimulated group, but actual counts were low at this eaiiy time point. At 48 hours 
in vitro, proliferation in the skin grafted group had increased to 3 fold greater than in 
the naive group and 5 fold greater than in the unstimulated group whilst at 72 hours 
proliferation in the skin grafted group had increased considerably to 5 fold greater 
than the naive group and 10 fold greater than in the unstimulated group. At 96 hours 
in vitro, the proliferation pattern in the 3 groups was similar to that at 72 hours and it 
was at these 2 time points that proliferation in the skin grafted group was at its 
greatest, with counts of 27 128 counts per minute (cpm) at 72 hours and 30 245 cpm 
at 96 hours. At 120 hours in vitro, proliferation in all groups had reduced 
considerably, although the pattern was the same as at the other time points. Values 
were calculated as the mean of 3 separate MLRs with 6 repetitions in each MLR.
As in vitro proliferative responses were most pronounced at 72 and 96 hours 
in vitro, it was decided in subsequent experiments to determine proliferative 
responses in each of the treatment groups at these 2 time points.
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4.3 MLR with cells taken from pre-treated animals
Both untreated and pre-treated C57B1/6 mice were grafted with BDFi tail skin 
and their spleens removed at various times after grafting. Mice were pre-treated with 
anti-IL-12 antibody alone, donor spleen cell injection alone or a combination of the 2 
treatments, as detailed below. Single cell suspensions were prepared from the spleens 
of grafted animals and cultured with irradiated BDFi cells. In vitro proliferative 
responses were assessed at 72 and 96 hours. The various treatment groups which all 
received BDFi skin grafts were: (i) unmodified recipients of a BDFi graft; (ii) mice 
pre-treated with 5x10^ BDFi spleen cells injected intravenously 1 week prior to skin 
grafting; (hi) mice pre-treated with donor spleen cells at day -7 and also given 
purified goat IgG, given as 0.5 mg. ip. on day -8, -5, -2 and 1 with grafting on day 0; 
(iv) animals pre-treated with donor cells on day -7 plus 0.5 mg. anti-IL-12 antibody 
ip. on day -8, -5, -2 and 1, and grafted on day 0; (v) mice ti'eated with anti-IL-12 
antibody alone on day -1,2,5 and 8, and grafted on day 0. The spleens were removed 
from animals 3, 7, 10 and 15 days after grafting and MLRs prepared as above. 
Results were calculated as the mean of 3 separate MLRs as before. The values 
expressed are the counts in each well minus the background counts from cultures of 
responder cells in medium alone, with no stimulation.
4.3.1 Results of MLRs with cells taken 3 days after grafting
Animals from each treatment group were sacrificed 3 days after grafting and 
MLRs prepared. At 3 days, results from such MLRs at 72 and 96 hours followed a 
similar pattern, shown in figure 4.2. With cells taken from naive animals, there were 
moderate levels of proliferation. With cells from umnodified graft recipients high
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.counts were detected at both time points with counts averaging approximately 30 000 
cpm at both time points, a 3 to 4-fold increase in proliferation compared to cells from 
naive animals. Counts were calculated as described before. Interestingly, cells taken 
from animals which had been pre-treated with donor cells 1 week prior to grafting 
showed little proliferation at either time point with counts averaging around 3 000 
cpm. This was the case with cells from grafted animals treated with donor spleen 
cells alone, or with those pre-treated with donor cells plus either anti-IL-12 antibody 
or purified goat IgG. Thus pre-treatment with donor spleen cells appeared to reduce 
the proliferative response in vitro to donor antigen, irrespective of additional 
treatments. In addition, there were no real differences between the treatment groups 
which had received donor cells in the pre-treatment protocol.
4.3.2 Results of MLRs with cells taken 7 days after grafting
Cells from unmodified animals grafted 7 days previously proliferated well at 
both time points and these results are shown in figure 4.3. As with cells taken from 
animals 3 days after grafting, cells from mice pre-treated with donor antigen either 
with or without additional treatment of anti-IL-12 antibody or goat IgG showed 
reduced proliferation compared to cells from unmodified graft recipients, with counts 
being reduced by half. These results were similar at both time points. Interestingly, 
cells taken from animals treated with anti-IL-12 antibody alone showed increased 
proliferation with counts compai'able to those from unmodified graft recipients. Thus 
at day 7 after grafting, cells from animals pre-treated with donor antigen continued to 
show reduced proliferation, but treatment with anti-IL-12 antibody alone did not 
affect proliferation in vitro.
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4.3.3 Results of MLRs from cells taken 10 days after grafting
Cells from unmodified graft recipients 10 days after grafting continued to 
show good proliferation, while those pre-treated with donor antigen, either with or 
without further antibody treatment, showed reduced proliferation, with counts being 
reduced some 2 to 3-fold (figure 4.4). As with day 7 after grafting, cells from graft 
recipients treated with anti-IL-12 antibody alone proliferated to a comparable degree 
to those from unmodified grafted animals.
4.3.4 Results of MLRs from cells taken 15 days after grafting
By day 15 after grafting, unmodified graft recipients and those pre-treated 
with donor spleen cells would both have rejected their grafts, while those pre-treated 
with donor cells plus anti-IL-12 antibody would only be starting to reject. At day 15 
after grafting, differences in proliferation between the various treatment groups was 
less marked. This was most obvious after 96 hours in vitro and these results are 
shown in figure 4.5. At this time, proliferation in all groups was similar, with cells 
from unmodified graft recipients achieving counts of 16 659 cpm, and those from
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grafted animals pre-treated with donor cells giving 13 669 cpm. Interestingly, the 
lowest counts achieved at this time was in the group pre-treated with donor cells plus 
anti-IL-12 antibody, with an average of 10 187 cpm. By day 15, therefore, the large 
differences seen in proliferation at earlier times with cells from umnodified graft 
recipients compared to those from animals pre-treated with donor cells had largely 
disappeared, although proliferation in the group treated with donor cells plus anti-IL- 
12 antibody was still lower.
I
It would appear, therefore, that injection of donor cells prior to grafting 
markedly reduces the proliferative response to donor antigen in vitro. This effect 
does, however, diminish with time. Such reduced proliferation in a MLR does not, 
however, correlate with prolonged graft survival as all treatment groups which 
received donor cell pre-treatment did not show prolonged graft survival, this only 
being exhibited in the group treated with both donor cells plus anti-IL-12 antibody.
4.4 Discussion
In this study, spleen cells cultivated from grafted mice pre-treated with donor 
antigen in the form of 5 x 10  ^donor spleen cells injected intravenously 1 week prior 
to skin grafting showed a reduced in vitro proliferative response on re-stimulation 
with donor strain spleen cells. This effect was not dependent on any additional 
treatment such as the neutralisation of endogenous IL-12. It is interesting to note that 
such reduced proliferation in vitro was not associated with a prolongation of skin 
graft survival.
These findings correlate well with previously published results. Josien et al 
(1999) have shown that, in a model of allograft tolerance induced by donor -specific 
transfusion in rats, such tolerance is characterised by inliibition of both T cell and 
macrophage activation. Such treatment profoundly inliibits proliferation of spleen 
cells from graft recipients re-stimulated with donor antigen in MLR. Kitagawa et al 
(1991, a) assessed proliferation in vitro in cells from mice which had been injected 
with MHC class I disparate spleen cells 1 week previously. They found that 
proliferation by cells from pre-treated animals re-stimulated with irradiated donor 
cells in vitro is comparable to background levels while proliferation is increased
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presented here because animals were not exposed to donor antigen in the form of a 
sldn graft prior to removal of cells for MLR. It does, however broadly agree with the 
findings presented here, namely that pre-treatment with donor cells leads to reduced 
responsiveness in a MLR.
some 10-fold in cultures of cells ftom animals which had not received donor cells. 
Increasing the number of cells given in the donor innoculum makes no difference. 
Most significantly, they reported that despite this reduction in proliferation in vitro, 
intravenous donor spleen cell injection does not prolong skin graft survival across a 
full MHC class I mismatch. They also determined that proliferation of both CD4^ and 
CDS’*" T cells is inhibited by donor cell injection in their model. Despite a profound 
reduction in MLR responses, CTL activity is not affected by donor specific 
transfusion, and it is these cells which are responsible for allograft rejection in their 
model.
This group had previously described how donor spleen cell injection in a class 
I minor mismatch model does markedly reduce proliferation in a MLR and is also
i
I
associated with significant prolongation of skin graft survival (Azuma et al, 1989).
fi
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They concluded that suppression of MLR, even though it can be profound, is not 
always correlated with a reduction in the capacity to reject grafts in vivo.
Other workers have investigated proliferative responses in MLR when 
C57B1/6 mice are injected with BDFi lymphoid cells (Kiziroglu and Miller, 1991), 
They reported that cells removed from C57B1/6 mice pre-treated with iv. donor cells 
fail to proliferate when re-stimulated with irradiated donor cells. It was concluded 
that injection of cells leads to inactivation of Th cells, although the exact mechanism
for this is unclear. This work is not, however, directly comparable to the work
I
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Donor-Specific cell injection prior to skin grafting in minor MHC class I and 
II mismatches is associated with a reduction in proliferative responses when cells are 
re-stimulated in a MLR, a reduction in CTL activity and prolongation of skin graft 
survival (Hori et al, 1989). Conversely, when fully disparate MHC class I strains are 
used, while there is a reduced response in a MLR, this is not associated with 
prolongation of skin graft survival. The results presented for the semi-allogeneic 
mismatch model used here support these findings. While pre-treatment with donor 
cells profoundly inliibited proliferation in a MLR, it did not prolong allograft 
survival. In addition, treatment with anti-IL-12 antibody alone had no effect on 
proliferation in vitro.
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4.5 Cytokine production in vitro
To investigate the production of cytokines in vitro, the supernatants of 
cultures of spleen cells from grafted C57B1/6 mice re-stimulated with irradiated 
donor cells were harvested. Initially, cells were removed from animals which had 
received BDFi tail skin grafts 3 days earlier or from animals which had not received 
a graft and cultures prepared. Cells were stimulated either with irradiated BDFi 
donor cells or with medium containing 10 pg/ml conA and cells cultured for 48, 72 
and 96 hours. These results are shown in figure 4.6. Supernatants were harvested at 
these time points and analysed for their content of IFN-y and IL-4 using sandwich 
ELISAs as described earlier. When spleen cells from grafted animals were stimulated 
with conA, IFN-y production was most marked at 72 hours, although levels of IFN-y 
were high at all 3 time points examined. Similarly with cells removed from grafted 
animals re-stimulated with donor antigen, IFN-y production was greatest at 72 hours 
in vitro, and, although levels were reduced compared to cells stimulated with conA, 
levels were still high. In cells from ungrafted animals stimulated with BDFi cells, 
production of IFN-y was low at all 3 time points.
When spleen cells from grafted animals were stimulated with conA they 
produced moderate amounts of IL-4 at all 3 time points examined, while spleen cells 
from graft recipients re-stimulated with donor cells produced smaller, although 
detectable levels of IL-4 at all 3 time periods, with no great differences between 
them. Spleen cells from ungraded animals stimulated with BDFi cells failed to 
produce much IL-4 at any time point.
As production of both cytokines appeared to be maximal after 72 hours of 
culture, supernatants were harvested from cultures of cells in the various treatment
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groups after 72 hours and sandwich ELISAs were carried out to quantify cytokine 
production. Spleens were removed from treated C57B1/6 mice at 3, 7, 10 and 15 days 
after grafting and MLRs prepared as before. The Thl cytokines IL-2 and IFN-y and 
the Th2 cytokines IL-4, IL-5 and IL-10 were quantified. Results were calculated 
using the mean of 3 separate ELISA assays from different cultures. Analyses were 
performed on C57B1/6 mice in each of the following treatment groups: (i) 
unmodified BDFi graft recipients; (ii) BDF i graft recipients pre-treated with 5x10^  
donor spleen cells iv. 1 week prior to grafting; (iii) BDFj graft recipients pre-treated 
with donor cells as before and 0.5 mg. anti-IL-12 antibody on day -8, -5, -2 and 1;
(iv) BDFi graft recipients given iv. donor cells as before plus 0.5 mg. goat IgG on 
day -8, -5, -2 and 1 as a negative control; (v) BDFi grafted animals treated with 0.5 
mg. anti-IL-12 antibody on day-1,2,5 and 8.
Spleen cells prepaied from animals in each of the treatment groups were 
cultured with irradiated BDFi splenocytes which acted as antigen-specific 
stimulators. Negative control cultures, where cells from grafted animals were 
cultured in standard medium alone, and positive control cultures, where splenocytes 
from animals in each of the treatment groups were cultured with standard medium 
containing 10 pg/ml conA were also prepared. The results of cytokine production in 
these cultures are shown in tables 4.1 to 4.5. At each time point, and in each 
experimental group, production of the various cytokines tested was not detectable in 
the cultures of cells from grafted animals cultured with standard medium alone. This 
indicates that there was no spontaneous production of cytokines by unstimulated 
cells. Splenocytes from animals in each of the treatment groups at all time points 
tested were, however, capable of producing detectable levels of cytokines when
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stimulated with the mitogen conA. These levels were similar in each of the treatment 
groups, indicating that splenocytes in each of the treatment groups were responsive to 
mitogens and that none of the treatments used induced non-specific suppressive 
effects. In the groups re-stimulated with irradiated donor strain cells there were, 
however, significant differences between the treatment groups and at the different 
time points examined. These differences are discussed in the following sections.
4.5.1 Production of IL-2 in vitro
With cells taken from animals 3 days after grafting and re-stimulated in vitro, 
IL-2 production was greatest in spleen cells obtained from umnodified graft 
recipients (figure 4.7). Spleen cells from this group produced twice the amount of IL- 
2 compared to cells from animals in any of the treatment groups and these differences 
were statistically significant (p<0.05) when compared using a Wilcoxon matched 
pairs test. Interestingly, all the other treatment groups assessed at day 3 after grafting, 
namely grafted animals pre-treated with donor cells, those pre-treated with donor 
cells plus anti-IL-12 antibody and those given donor cells plus goat IgG produced 
comparable, but reduced amounts of IL-2.
Production of IL-2 by cells removed 7 days after grafting was broadly similar 
in all the experimental groups, including those treated with anti-IL-12 antibody alone, 
with all groups producing around 15 u/ml and there were no significant differences 
between groups. At 10 days after grafting, IL-2 production was slightly elevated in 
the groups which had been pre-treated with donor spleen cells, either with or without 
antibody, with production around 10 u/ml. However, differences were small and 
standard deviations were relatively large and so such differences were not significant.
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Interestingly, at day 15, production of IL-2 was also increased in all the treatment
groups compared to umnodified grafted animals although again differences were
small. These differences were, however, significant in the groups treated with donor
cells alone or with donor cells plus goat IgG, but not in the groups treated with anti-
IL-12 antibody, either with or without donor cells.
Thus IL-2 production was increased in cells from unmodified grafted animals
compared to all the other treatment groups early on in the rejection process.
However, as time went on, IL-2 production was similar in all groups and latterly was
.increased in groups which had received donor cells without anti-IL-12 antibody. It is
.of interest to note that pre-treatment with donor cells either with, or without anti-IL- 
12 antibody was capable of reducing IL-2 production early after grafting even though 
pre-treatment with donor cells alone did not correlate with prolonged skin graft 
survival. In addition, treatment with purified goat IgG plus donor cells had no effect 
over and above treatment with donor cells alone.
4.5.2 Production of IFN-y in vitro
The cells from unmodified graft recipients taken 3 days after grafting 
produced considerably more IFN-y than those from the other groups, that is those 
treated with donor cells either with or without anti-IL-12 antibody or goat IgG.
Results are shown in figure 4.8. In the unmodified grafted group, IFN-y production 
was some 20 fold greater compai'ed to the other groups, all of which were very
similar' and these differences were statistically significant (p<0.05). Cells taken 7 
days after grafting from treated animals all produced more IFN-y than those from 
umnodified graft recipients with little differences between the groups treated with
■I
in
donor cells either with or without additional antibody. This increase was, however, 
modest, being approximately twice that of unmodified graft recipients although the 
differences were significant. At this time the greatest production of IFN-y was seen in 
cells taken from grafted animals treated with anti-IL-12 antibody alone. Despite this, 
levels of IFN-y production by cells from mice 3 or 7 days after grafting are relatively 
low.
The most dramatic differences in IFN-y production were seen at the later time 
points. At 10 days after grafting, cells from unmodified graft recipients produced 
large amounts of IFN-y, averaging 51.7 u/ml. In addition, production of IFN-y in the 
groups pre-treated with donor cells, either with or without additional antibody, 
remained similar to that seen at the earlier time points for the same groups. Thus, 10 
days after grafting, IFN-y production by cells from animals which had received pre- 
treatment with iv. donor spleen cells was 50 times less than in the unmodified grafted 
group, at around 1.0 u/ml. Cells from animals treated with anti-IL-12 antibody alone 
produced elevated amounts of IFN-y compared to the other treatment groups, 
recording levels of 27.0 u/ml.
At day 15 after grafting, production of IFN-y was similar to that seen at day 
10 in the various treatment groups. Cells from unmodified graft recipients produced 
large amounts, cells from animals treated with anti-IL-12 antibody alone produced 
moderate amounts and cells from animals pre-treated with donor spleen cells either 
with or without further antibody treatment produced small amounts.
IFN-y production in unmodified graft recipients was, therefore, high. 
However, when mice are pre-treated with iv. donor spleen cells, production was 
considerably reduced and this was statistically significant. This reduction appeared to
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4.5.3 Production of IL-4 in vitro
treatment groups (figure 4.9). Ceils removed from animals 3 days after grafting all 
produced small amounts of IL-4 upon re-stimulation, although a statistically
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'ibe dependent on donor cell injection rather than additional antibody treatment, either 
with anti-IL-12 antibody or goat IgG, as levels were equally reduced in all 3 groups. 
Treatment with anti-IL-12 antibody alone did reduce IFN-y production to a moderate 
level, but this was always considerably higher than in the groups treated with donor 
cells. Thus treatment with anti-IL-12 antibody alone did not completely prevent 
production of IFN-y in this model, while treatment with donor cells was more 
effective.
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Production of IL-4 in cultures showed small differences between the various
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significant reduction was seen in the groups treated with donor cells either with or
without goat IgG, but not in the groups treated with anti-IL-12 antibody. At day 7,
i.
however, production of IL-4 was increased in cells from animals pre-treated with 
anti-IL-12 antibody, either with or without donor spleen cells. IL-4 production was 
12.7 u/ml in the group treated with anti-IL-12 antibody plus donor spleen cells and 
12.5 u/ml in the group treated with anti-IL-12 antibody alone compared to 6.4 u/ml in 
cells from unmodified graft recipients, although such differences were not 
significant. At 10 days after grafting, IL-4 production was greatest in cultures from 
umnodified graft recipients with this being twice the level detected in the other 
groups and this was statistically significant. At day 15, the pattern was similar to that 
seen at day 7, with groups which had received anti-IL-12 antibody pre-treatment,
either with or without donor cells, showing a slight increase in IL-4 production 
compared to other groups.
Thus pre-treatment with anti-IL-12 antibody tended to promote IL-4 
production by re-stimulated cells compared to the groups which had not received it. 
The differences observed were, however, small, the maximum increase in IL-4 
release being only 2 fold. In addition, there were no real differences in the production 
of IL-4 by cells from mice pre-treated with anti-IL-12 antibody alone compared to 
those treated with both anti-IL-12 antibody and donor spleen cells. Interestingly, 
treatment with donor cells alone appeared to reduce IL-4 production compared to 
other groups.
4.5.4 Production of IL-5 in vitro
At day 3 after grafting, only cells obtained from mice pre-treated with anti- 
IL-12 antibody plus donor spleen cells produced detectable levels of IL-5 on re­
stimulation in vitro. These results are shown in figure 4.10. In unmodified grafted 
controls and in those treated with donor cells or donor cells plus goat IgG, IL-5 was 
undetectable. With cells removed 7 days after grafting, IL-5 production was confined 
to cells from animals which had been pre-treated with anti-IL-12 antibody, either 
with or without donor cells. In the other 3 groups, IL-5 was undetectable. 
Interestingly, at this time, production of IL-5 in the group treated with anti-IL-12 
antibody alone was less than half that of the group treated with both anti-IL-12 and 
donor cells.
Cells from animals in all the treatment groups produced small amounts of IL- 
5 when cultured 10 days after grafting with no real differences between the groups.
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However, 15 days after grafting, the group treated with both anti-IL-12 and donor
.cells produced large amounts of IL-5, with little or none being detected in the other 
groups.
Significant production of IL-5 was, therefore, confined to cultures of cells 
from mice which had been pre-treated with anti-IL-12 antibody. This was greatest in 
the group treated with both anti-IL-12 antibody and donor spleen cells, suggesting 
that both treatments together produced a stronger cytokine response. Treatment with 
donor cells alone, or no treatment at all, did not promote the generation of IL-5.
4.5.5 Production of IL-10 in vitro
In cultures of cells removed 3 days after grafting, IL-10 production was 
detectable in all of the treatment groups, but was most pronounced in the group 
treated with both donor spleen cells and anti-IL-12 antibody (figure 4.11). These 
differences were not, however, significant. Production was lowest in the group 
treated with donor cells, either with or without goat IgG control antibody, and these 
were 2 fold less than in the highest group. By day 7 after grafting, production of IL-
10 was greatest again in the group treated with both donor cells plus anti-IL-12
antibody, with this being 3 times greater than that in the unmodified grafted group or 
in those pre-treated with donor cells alone and this difference was significant
(p<0.05). In the group treated with anti-IL-12 antibody alone, IL-10 production was 
slightly increased compared to unmodified graft recipients.
IL-10 production by cells removed 10 days after grafting was considerably 
increased in the group pre-treated with donor cells plus anti-IL-12 antibody, with this 
being increased 5 fold compared to all other groups and again this was significantly
-M:
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increased. Cells from animals which had been grafted 15 days earlier all produced 
detectable levels of IL-10 when re-stimulated in vitro. Interestingly, at this time 
levels were greatest in the groups treated with donor spleen cells, either with or 
without goat IgG. In the groups treated with anti-IL-12 antibody, with or without 
donor cells, IL-10 production at this time was reduced, although the differences 
between groups at this time were not statistically significant.
Thus, at the earlier time points after grafting, pre-treatment with anti-IL-12 
antibody, either with or without donor spleen cell injection, promoted IL-10 
production in vitro. This was considerably more pronounced when both treatments 
were combined. At the later time points, differences between the groups were much 
less obvious.
4.6 Discussion
In this experimental model of semi-allogeneic skin grafting in mice, 
unmodified rejection was associated with a strong Thl cytokine response as 
determined by cytokine measurements in cultures of spleen cells from grafted 
animals. When cells from skin grafted animals were re-stimulated with donor- 
specific antigen in vitro there was an early increase in IL-2 production at 3 days after 
grafting, followed by a large increase in IFN-y production as rejection became 
established. In addition, there was little Th2 cytokine production during rejection. 
Cytokine production was seen to be a dynamic process, with different cytokines 
being produced in greater or lesser amounts at different times after grafting. Such 
findings support the results of many other workers. Gorczynski and Kiziroglu (1994) 
found that cells removed from animals which had received a minor MHC ■i
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mismatched skin graft 7 days earlier and re-stimulated in vitro with donor antigen 
produce elevated levels of IL-2 and IFN-y. Takeuchi et al (1992) demonstrated 
increased transcripts of niRNA for Thl cytokines in their model of unmodified 
rejection of cardiac allografts in mice. They found that message for IFN-y is greatest 
5 days after grafting and declines thereafter. Equally, message for IL-2 is greatest 5 
days after grafting and then decreases.
Levels o f IFN-y in this model were greatest around the time of rejection in 
unmodified grafted animals (day 10). However, the highest levels of IL-2 were found 
much earlier than this (day 3) and, by the time of rejection, levels of IL-2 were 
actually less than in other groups. Takeuchi et al (1992) also found that the peak IL-2 
production preceded graft rejection in their model of a murine cardiac allograft where 
tolerance was induced by treating recipient mice with donor specific transfusion, 
cyclosporin or anti-CD4 mAh. O’Comiell et al (1993) demonstrated that rejection of 
unmodified recipients of murine pancreatic islet cell grafts is preceded by the 
production of IL-2 within the graft as detected by polymerase chain reaction-assisted 
reverse transcription. In addition, production of IL-4 during unmodified islet cell 
rejection was not detected. More recently, it has been demonstrated that umnodified 
rejection o f pancreatic islet cell grafts in mice is associated with increased expression 
of IL-2 and IFN-y, with levels of IL-4 barely detectable ( Li et al, 1998). Thus these 
results, and the results presented here, demonstrate that unmodified rejection is 
characterised by a strong Thl response although the levels of cytokine production at 
various times do differ.
Pre-treatment of graft recipients with iv. donor spleen cells 1 week prior to 
grafting altered the cytokine producing potential of cells re-stimulated in vitro. In
117
culture, such cells failed to produce large amounts of the Thl cytokines at any time 
point examined. Most significantly, levels of IFN-y were markedly reduced compared 
to those from umnodified grafted groups. Pre-treatment with donor cells also failed to 
induce any significant increase in the production of Th2 cytokines. Such a reduction 
in Thl cytokine generation did not, however, correlate with any increase in allograft 
survival. Results for the negative control group where mice were treated with donor
cells plus purified goat IgG were similar to those for cells from animals treated with 
donor cells alone. Cells from animals pre-treated with donor cells were, however, 
able to produce detectable levels of cytokines when stimulated with mitogens, 
indicating that this reduction in cytokine production was antigen specific. Other 
workers have reported similar findings. Kitagawa et al (1991, a) described how 
donor-specific cell injection prior to skin grafting reduces proliferative responses and 
IL-2 production in vitro when cells are re-stimulated with donor antigen. Graft 
rejection in their model is due to CD8^ CTL which are resistant to donor cell pre­
treatment, and so skin graft sm*vival is not prolonged by injection of donor cells 
alone. However, when donor cell pre-treatment is combined with anti-CD8 mAh 
therapy, skin graft survival is significantly prolonged. It was concluded that pre-
.treatment with donor cells induces elimination, or functional inactivation of |
.particular T cell subsets, but this does not necessaiily equate with prolongation of I
.graft survival. Only when donor cell injection is combined with treatments 
eliminating either CD8^ CTL or CD4^ Th cells is graft survival increased
Dallman et al (1991, a) demonstrated in a rat kidney allograft model that . i
donor-specific transfusion produces long term graft survival and that the resulting 
transplantation tolerance is associated with reduced IL-2 production by tolerant cells
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ill vitro. They concluded that donor-specific transfusion induces T cell anergy by 
alloantigen stimulation in the absence of a second signal and that this is the 
mechanism for aeeeptance of kidney grafts. Bugeon et al (1992) extended this work 
and found that donor-specific transfusion prior to grafting leads to decreased levels of 
both IL-2 and IFN-y mRNA in the cardiac allografts of tolerant animals.
In the model used in this thesis, pre-treatment with donor cells led to reduced 
levels of both Thl and Th2 cytokine production. It did not, however, result in 
prolonged graft survival and so, while T cells may have been rendered um'esponsive 
in terms of cytokine production, animals were still capable of effecting allograft 
rejection. The underlying mechanism behind the blood transfusion effect remains 
unresolved. However the results presented here suggest that the generation of a Thl 
environment is not an absolute requirement for allograft rejection and that other 
mechanisms may also be involved in activating the cells which mediate allograft 
rejection in this model. This is supported by other workers findings. For example, 
VanBuskirk et al (1996) demonstrated that allograft rejection can proceed in the 
absence of Thl cells.
Pre-treatment of skin graft recipients with anti-IL-12 antibody alone did not 
prolong allograft survival. However, when cells from such animals were removed 
and re-stimulated in vitro, diminished Thl and increased Th2 cytokine responses 
were produced. Interestingly, while pre-treatment with anti-IL-12 antibody reduced 
production of IFN-y, it did not abolish it, or reduce it to the levels produeed by cells 
from animals pre-treated with donor spleen cells. Thus neutralising endogenous IL- 
12 did not prevent the generation of IFN-y, indicating that IL-12 is not the only signal 
required for IFN-y production. Treatment with anti-IL-12 antibody did, however push
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cells towards a Th2 phenotype with increased levels of IL-5 and IL-10 being
generated in vitro. Piccotti et al (1996) found similar effects in a murine cardiac
allograft model. They found that neutralising endogenous IL-12 leads to increased
mRNA for IL-4 and IL-10, although message for IFN-y is still present. In addition,
when spleen cells are removed from treated animals and re-stimulated in vitro, they
can still produce IFN-y. Thus while neutralising IL-12 induces a shift towards a Th2
response, the Thl response is not completely abrogated. In addition, this shift
towards a Th2 response does not prolong cardiac allograft survival. Similarly, Li et al
(1998) found that, in a mouse pancreatic allograft model, while pre-treatment with
anti-IL-12 antibody did induce a Thl to Th2 cytokine shift, this was not associated
with prolonged allograft survival in MHC-mismatch strain combinations.
In this model, despite treatment with anti-IL-12 antibody alone generating a
Th2 response, allograft survival was not prolonged. This may be because not all Thl
cytokine production was prevented. IL-18, a recently identified cytokine, induces
.production of IFN-y and thus an alternative pathway for the generation of Thl
■I
responses exists (Okamura et al, 1998). Allograft rejection may proceed by activation 
of this alternative pathway. Equally, anti-IL-12 antibody treatment alone only 
generated a weak Th2 response compared to treatment with both anti-IL-12 antibody
and donor spleen cell injection. Such a weak Th2 response may be insufficient to 
overcome the Thl response which still exists.
production of the Thl cytokines was reduced and that of the Th2 cytokines increased.
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Pre-treatment of graft recipients with both anti-IL-12 antibody and donor
.spleen cells significantly prolonged the survival of skin allografts. When 
immunocompetent cells were removed from such animals and re-stimulated in vitro,
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Donor antigen pre-treatment appears, therefore, to have additive effects with anti-IL-
12 antibody in terms of Th2 cytokine production because levels of Th2 cytokines in
this group were greater than those in the group treated with anti-IL-12 antibody
alone. Thus prolonged allograft survival was associated with a Th2 response. One
explanation for this may be that, while pre-treatment with anti-IL-12 alone is
insufficient to polarise the immune response strongly in a Th2 direction, once a
strong Th2 response is generated allograft survival can be prolonged. However, in the
group treated with anti-IL-12 antibody and donor spleen cells, while skin graft
survival is prolonged, grafts are not accepted permanently. At day 15 after grafting,
cells from animals pre-treated with both anti-IL-12 antibody and donor cells continue
.to produce elevated Th2 cytokines with very little IFN-y, indicating that a Th2 
response in itself does not necessarily equate with tolerance as skin grafts are rejected 
not long after this.
The assumption has been made that while a Thl response is associated with 
allograft rejection, conversion to a Th2 response may be associated with tolerance.
The results presented in this study do not support this. A weak Th2 response, 
generated by treatment with anti-IL-12 antibody alone, had no effect on allograft 
survival, while a strong Th2 response, generated by donor cell plus anti-IL-12 pre­
treatment, did prolong allograft survival by a few days but, even in the absence of 
Thl response, rejection did still occur. Similar findings have been reported. Chan et 
al (1995) depleted CD8  ^T cells in a murine cardiac allograft model and found that 
this had no effect on allograft survival compared to unmodified controls. They did, 
however, find that the rejection mechanisms were different: unmodified rejection was 
associated with a heavy CTL infiltrate and the generation of Thl type cytokines;
3
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rejection in CDS’*" T cell-depleted animals was associated with a reduced CTL 
infiltrate, a heavier eosinophil infiltrate and Th2 cytokine production. They 
concluded that while the ultimate effector mechanisms were different, allograft 
rejection could still occur in either a Thl or a Th2 environment. They therefore 
questioned the relevance of the Thl / Th2 paradigm in transplantation. More recently, 
Jo sien et al (1999) demonstrated that DST prior to grafting in a rat allogeneic heart 
graft model induced long term graft survival, and this was assoeiated with down- 
regulated production of cytokines within the graft. Treatment with recombinant IFN-y 
abolished the beneficial effect of DST, but this was not associated with any change in 
the cytokine profiles from treated animals. Rather, treatment with rIFN-y enhanced 
anti-donor IgG alloantibody production and it was this which induced rejection, 
indicating that, even in the presence of a down-regulated cytokine response, humoral 
immunity can induce allograft rejection. Similarly, Yang, C.P. et al (1998) 
demonstrated that DST can iduce long-term graft survival when rejection is 
dependent on cell-mediated events, but not when it is mediated by humoral 
mechanisms.
The results presented here would also challenge the idea that a Th2 response 
is necessarily associated with tolerance. At day 15 after grafting, lymphoid cells from 
animals pre-treated with donor spleen cells and anti-IL-12 antibody continued to 
produce Th2 cytokines with little evidence of Thl cytokine production, but the skin 
grafts rejected around day 17. It may be, therefore, that other mechanisms rather than 
T hl/ Th2 deviation account for the prolongation of allograft survival seen in these 
studies. Additional experiments performed to investigate this possibility are 
described in the following chapter. Alternatively, it must be appreciated that
%■
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achieving tolerance to skin grafts is extremely difficult and it is possible that
.treatment with both anti-IL-12 antibody and donor spleen cells, effecting a deviation
.in the immune response from Thl to Th2, may prove to be effective in inducing
transplantation tolerance in a less exacting experimental model such as allogeneic 
cardiac transplantation.
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4.7 Summ ary of Results of C hapter 4
1. Preparations of cells from the spleens of treated animals proliferate in vitro 
when stimulated with irradiated donor cells. Pre-treatment of graft recipients with 
injected donor cells prior to skin grafting reduced the proliferation of such spleen
cells irrespective of any other treatment which recipient animals received.
3. Cells prepared from the spleens of unmodified skin graft recipients produce 
increased amounts of the Thl cytokines IL-2 and IFN-y when re-stimulated in vitro 
with donor alloantigen.
124
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2. Cells prepared from the spleens of skin graft recipients pre-treated with 
anti-IL-12 antibody alone did not exhibit reduced proliferative responses.
I
■ a
. .4. Cells from the spleens of skin graft recipients pre-treated with injected a
donor spleen cells prior to grafting produce reduced levels of both Thl and Th2 
cytokines when re-stimulated with donor alloantigen in vitro.
,5. Spleen cells from skin graft recipients pre-treated with anti-IL-12 antibody 
alone produce reduced levels of Thl cytokines and low levels of Tli2 cytokines when
re-stimulated in vitro.
aI
.6. Spleen cells from grafted animals pre-treated with both anti-IL-12 antibody 
and donor spleen cells prior to grafting produce low levels of Thl cytokines and
increased levels of the Th2 cytokines, IL-5 and IL-10, and this treatment regime is 
associated with prolonged skin graft survival.
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Figure 4.1 Proliferation in a MLR at various time points. Spleens were 
removed from C57B1/6 mice and single cell suspensions prepared. Cells were 
re-stimulated in vitro with irradiated BDFi cells and maintained in vitro for 24, 48, 
72, 96 or 120 hours after which 3H thymidine was added and, 18 hours later, 
proliferation quantified. The responder cell types examined were: cells from naïve, 
ungrafted animals (ungrafted); cells from animals which had received a BDFi 
tail skin graft 3 days earlier (BDF i - Bl/6); cells from animals which had received 
a skin graft 3 days earlier but had no stimulator cells added to the MLR 
(unstimulated). Counts are the means of 3 experiments +/- 1 standard deviation.
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Figure 4.2 Proliferation in vitro by eells 3 days after grafting. Spleen cells 
were removed from C57B1/6 mice and re-stimulated in vitro with irradiated 
BDFi cells. Cultures were harvested at 72 and 96 hours in vitro. Proliferation 
was quantified in the following groups: (i) ungrafted - cells removed from naïve 
mice; (ii) unmodified graft - cells removed from mice which had received a 
BDF 1 skin graft 3 days previously; (iii) graft + donor cells - cells removed from 
animals which had been pre-treated with iv donor cells 7 days prior to receiving 
a skin graft; (iv) graft + cells + goat IgG - cells from animals pre-treated with 
both donor cells on day -7 and 0.5 mg goat IgG ip on days -8, -5, -2 and 1 ;
(v) graft + cells + aIL-12 - cells from mice pre-treated with donor cells on 
day -7 and 0.5 mg anti-IL-12 antibody on days -8, -5, -2 and 1. Counts are the 
means of 3 separate experiments +/- 1 standard deviation.
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Figure 4.3 Proliferation in vitro of cells removed 7 days after grafting.
MLRs were prepared as before from cells removed from C57B1/6 mice 7 days 
after grafting and maintained in vitro for 72 or 96 hours. Experimental groups 
are as for Figure 4.2 except the group graft + aïL-12 where mice were treated 
with 0.5 mg anti-IL-12 antibody on day -1,2,5 and 8 with grafting on day 0.
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Figure 4.4 Proliferation in vitro of cells removed 10 days after grafting.
MLRs were prepared as before with cells removed from C57B1/6 mice 10 
days after grafting. Experimental groups are as for Figure 4.3.
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Figure 4.5 Proliferation in vitro of cells removed 15 days after grafting.
Cells were removed from C57B1/6 mice 15 days after grafting with BDFi 
tail skin. Treatment groups were as for Figure 4.3.
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Figure 4.6 Quantification of cytokines produced in vitro. Cells were removed 
from C57B1/6 mice which had received a BDFi skin graft 3 days earlier or which 
had received no treatment and cultures prepared. Cells from grafted animals were 
restimulated with irradiated donor cells (BDFi - Bl/6) or with medium containing 
10 pl/ml conA (conA). Cells from animals which had not received a graft were 
stimulated with irradiated BDFi cells (ungrafted). Supernatants were harvested at 
48, 72 and 96 hours and cytokine content measured by ELISA. Values are expressed 
as the mean of 3 experiments.
Day 3
I
Day 7
30
20
10
0ii
Day 10
20
10
0
Day 15
30 T
20
10 -L i
<D11+ (UIi"P
ND
8 2
+ db
I “+ ^If
i_
i .Ii
Figure 4.7 Production of IL-2 in vitro. Spleens were removed from treated 
C57B1/6 mice which had received a BDFi skin graft at different time points after 
grafting (day 3,7, 10 and 15), and single cell suspensions prepared. These cells 
were re-stimulated in vitro with irradiated BDFi cells. Supernatants were harvested 
after 72 hours and analysed for IL-2 content by ELISA.
Treatment groups are as for Figure 4.2. and 4.3.
ND = not done. Values are expressed as the mean of 3 experiments +/- 1 standard 
deviation (SD), as are all further cytokine experiments. denotes statistical 
significance compared to results for umnodified graft recipients (p<0.05) using 
Wilcoxon matched pairs test.
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Figure 4.8 Production of IFN-y in vitro. Results are expressed as mean +/- SD.
* denotes statistical significance compared to results for unmodified graft recipients
(p<0.05). ND = not done.
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Figure 4.9 Production of IL-4 in vitro. Results are expressed as mean +/- SD,
denotes statistical significance compared to results for umnodified graft recipients
(p<0.05). ND = not done
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Figure 4.10 Production of IL-5 in vitro. Results are expressed as mean +/- SD.
^ = not detected. ND = not done.
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Figure 4.11 Production of IL-10 in vitro. Results are expressed as mean +/- SD.
denotes statistical significance compared to results for unmodified graft recipients
(p<0.05). ND = not done.
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CHAPTER 5
CYTOTOXICITY ASSAYS
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5.1 Introduction
Cytotoxic T cells recognise and kill target cells by direct cell-cell contact.
Both CTL and NK cell activity was, therefore, assessed in the experimental model 
presented here. Single cell suspensions from the spleens of treated animals were 
used for in vitro cytotoxicity analysis. Specific cytotoxicity by CTL and non-
127
CTL binding to an appropriate target stimulates a calcium-dependent 
degranulation process in the effector cell releasing perforin and granzyme from
secretory granules into the local enviromnent. This leads to the formation of pores 
in the target cell membrane and this is followed by fragmentation of the target cell 
DNA and cell lysis. A second, non-secretory pathway has also been proposed 
(reviewed in Berke, 1995) where the CTL induces apoptosis of the target cell via 
specific cell surface molecules such as Fas, and this may also be important in CTL
killing. CTL are thought to play an important role in allograft rejection. Rosenberg 
et al (1987) demonstrated that skin allograft rejection in mice occurred only in 
animals which possess both T helper and cytotoxic T cells specific for 
alloantigens within the graft. Hori et al (1992) demonstrated that mouse skin graft 
rejection is associated with a potent induction of allospecific CTL responses. 
When such CTL responses are inhibited following donor-specific transfusion, skin 
graft survival is significantly prolonged.
CTL are usually CD8^ T cells and thus respond to class I MHC 
alloantigen. However, some CTL are CD4^ T cells and are thus reactive against
MHC class II alloantigen (Rosenberg and Singer, 1992). IL-12 promotes specific 
CTL responses and can entrance the lytic activity of NK cells (Gately et al, 1998).
1
specific cytotoxicity by NK cells was quantified in each of the experimental 
groups
5.2 Specific Cytoxicity 7 Days after Grafting
Specific CTL activity in C57B1/6 animals which had received a BDFi skin
graft was assessed in spleen cell cultures prepared from spleens removed from
animals 7 and 10 days after grafting. Two different target cell types were used,
namely that of conA blasts prepared from DBA/2 mouse spleen cells (H2^) and
P815 cells. The latter cell line constitutively expresses F12^ . Thus if CTLs 
.specifically directed against the allo-MFIC of BDF i cells were present, lysis of 
both types of target cell would occur.
Cells prepared from spleens removed 7 days after grafting from 
unmodified graft recipients produced killing of DBA/2 conA blasts of 40 % at an 
effector:target cell ratio of 100:1 and this reduced as the ratio decreased. Results 
are shown in Figure 5.1. Cells from animals pre-treated with 5 x 1 0 ^  BDFi spleen 
cells iv. 7 days prior to grafting also produced similar levels of target cell killing 
in vitro when targets were conA blasts. Cells from mice pre-treated with 5 x 1 0 ^  
donor cells on day -7 and 0.5 mg. anti-IL-12 antibody ip. on days -8, -5, -2 and 1
I
?
showed levels of target cell killing which were slightly reduced compared to the
previous 2 groups. However, the differences between the groups are relatively 
small. The results shown are that of one experiment , but each experiment was 
repeated and produced similai* results.
Spleen cells prepared from the spleens of mice 7 days after grafting were 
also tested against P815 target cells (figure 5.2). In this experiment, target cell
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lysis was comparable in all 3 groups tested, that is cells from unmodified graft 
recipients, those from animals pre-treated with donor cells alone and those from 
animals treated with both anti-IL-12 antibody and donor cells. Thus, against P815 
targets at day 7 after grafting, pre-treatment of animals did not appear to affect 
CTL activity.
5.3 Specific Cytotoxicity 10 Days after Skin Grafting
Cells were obtained from animals in each of the 3 groups 10 days after 
grafting and CTL activity assessed against both DBA/2 conA blasts and P815 
cells. At day 10, the percentage cytotoxicity in each group was somewhat lower 
than in each group at day 7. As with day 7 after grafting, CTL activity was 
detectable in all groups but there were no real differences between percentage 
cytotoxicities when measured against DBA/2 conA blasts. These results are shown 
in Figure 5.3.
When CTL activity in cells removed 10 days after grafting was assessed
using P815 cells as targets, percentage cytotoxicity was lower than at day 7 (figure
5.4). However, at this time, CTL activity was similar in cells from unmodified
grafted animals and in those pre-treated with donor cells alone. By contrast, CTL
activity in the group treated with both anti-IL-12 antibody and donor spleen cells
was lower. Thus at day 10 after grafting there was little difference between the
groups in CTL activity against DBA/2 conA blasts, whilst against P815 cells CTL
activity was reduced in the group which exhibited prolonged graft survival. This 
.difference is difficult to explain. Against P815 targets, however, levels of killing 
were generally low and so differences between groups are small.
9:
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These results must, however, be interpreted with some caution. While in 
some groups pre-treatment with both donor cells and anti-IL-12 antibody did 
appear to reduce CTL activity, this was, by no means, a consistent finding at both 
time points or against both target cell types.
5.4 Non-specific Cytotoxicity
CD8  ^ CTL and NK cells represent 2 major populations of cytotoxic 
lymphocytes, both cell types being able to kill tumour cells, MHC-incompatible 
grafted cells and autologous cells infected with intracellular pathogens such as 
viruses (Austin and Wood, 1993). While CTL killing requires T cell help to 
generate effector cytotoxic cells, NK cells exist as pre-activated cytotoxic cells 
capable of mediating their effector function without the need for T cell help, 
making them an important component of the innate immune system (Kos and 
Engelman, 1996). IL-12 activates NK cells, increasing their cytotoxic activity and 
secretion of cytokines (Trinchieri, 1995) and so it could be assumed that, by 
inhibiting the activity of endogenous IL-12, NK cell activation could be prevented. 
NK cells have been proposed as the cell type responsible for the elimination of 
injected BDFi cells in parental strain recipients (Sheng-Tamier and Miller, 1992) 
and so, by inhibiting NK cell activation, destruction of injected donor-specific 
cells may be prevented, allowing persistence of such donor cells for longer within 
the host. Thus persistence of donor antigen after anti-IL-12 antibody treatment 
may potentially explain the prolonged skin graft survival in this group.
To investigate this, NK cell activity was assessed in vitro using a ^*Cr 
release cytotoxicity assay and the NK cell target cell, YAC-1 as described in
130
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injected ip 24 hours prior to spleen cell injection as in the control group. Donor
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ilWilliamson et al (1996), Spleens were removed from experimental animals, single 
cell suspensions were prepared and the cells were incubated with ^^Cr-labelled 
YAC-1 cells. Spleen cells were tested from untreated naive animals, animals pre­
treated with 5x10^  BDFi cells injected iv. 24 hours previously, and animals pre- 
_treated with 5 x 10 BDFi cells iv. 24 hours previously plus 0.5 mg. anti-IL-12
l l
antibody ip. 24 hours prior to that. Results are those from 1 experiment but are
representative of 2 further repetitions and are shown in figure 5.5.
The percentage cytotoxicity in the unmodified, naive group was 40 % for
an effector: target cell ratio of 100:1 and steadily fell as the ratio of effector to
target cells was reduced. In mice which had been pre-treated with BDFi cells , the
percentage cytotoxicity was consistently increased compared to the naive group,
indicating that, when animals are pre-treated with allogeneic cells iv., NK cell 
. . . .activity is increased. Interestingly, in the group treated with both donor cells and 
anti-IL-12 antibody, the percentage cytotoxicity was consistently reduced 
compared to naive controls. Thus treatment with anti-IL-12 antibody inhibits NK 
cell activity in this model.
■ i
5.5 Persistence of Donor Antigen
The persistence of injected donor strain cells within recipient mice was 
assessed using FACS analysis. Control C57B1/6 mice were injected with 5 x 1 0 ^
BDFi cells intravenously and their spleens and lymph nodes harvested 24 and 72 
hours later. Other C57B1/6 mice were treated with anti-IL-12 antibody or goat IgG
cells were labelled with FITC and quantified as a percentage of the spleen or 
lymph node cell population of the recipient animals.
At 24 hours after spleen cell injection, only small numbers of donor BDF; 
cells were detectable in either of the treatment or control groups, and these levels 
were at the threshold of detection. There were no differences in the percentages 
detected in each of the groups. These results are shown in Table 5.1 and are 
expressed as the means of 3 repetitions of each experiment.
Similarly, at 72 hours after spleen cell injection, the percentage of BDF; 
cells detectable in the spleens and lymph nodes of C57B1/6 mice in the control or 
treated groups was again very small, and no real differences were seen between 
the groups (Table 5.2).
Thus, in this experimental model using FACS analysis of spleen and 
lymph node cell populations, no differences were obseiwed in the survival of 
donor cells in the group treated with anti-IL-12 antibody compared to unmodified 
controls.
5.6 Discussion
In this study, the results of specific cell mediated cytotoxicity were 
equivocal. While treatment with both donor-specific spleen cells plus anti-IL-12 
antibody reduced CTL activity in some experiments, it was not a consistent 
finding at both time points against both target cell types. Pre-treatment with donor 
spleen cells alone did not reduce CTL activity. IL-12 is one factor responsible for 
the activation of CTL (Trinchieri, 1995) and thus, had reduced cytotoxicity been 
demonstrable in the groups treated with anti-IL-12 antibody, this may have
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explained the mechanism whereby prolonged allograft survival was achieved in 
this model.
Other workers have demonstrated the importance of inhibiting CTL 
activity in allograft survival. Kitagawa et al (1991, a) showed that while donor cell 
injection prior to skin grafting generally inliibited MLR responses to alloantigen in 
vitro, allograft survival was prolonged only if CTL activity was also reduced. 
They concluded that iv. pre-treatment with donor cells resulted in the elimination
!■
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of the proliferative and IL-2-producing capabilities of host CD4"  ^and CD8^ T cells
Îwithout affecting the capacity of CD8 CTL precursors to reject the graft. Donor
cell pre-treatment prior to skin grafting in a class I MHC mismatch was able to
prolong allograft survival only when combined with anti-CD8 mAh therapy
(Kitagawa et al, 1991, b). The results described in the present study correlate well 
,with these. However, additional treatment with anti-IL-12 antibody did not 
consistently reduce CTL activity in vitro. It can be concluded, therefore, that IL-12
is not the only factor required for CTL activation. Thus, in this model of 
prolonged skin graft survival, inhibition of CTL activity did not appear to be the
mechanism whereby graft survival was increased. Similar findings have been 
reported by Piccotti et al (1996), who found that CTL invasion of vascularised 
heart grafts is not influenced by antagonism of endogenous IL-12. Neutralising IL- 
12 did not prevent CTL invading allogeneic cardiac grafts, and rejection was not 
prevented by this treatment. IL-18, (IGIF) has recently been demonstrated to 
synergise with IL-12 in the generation of IFN-y production and in Thl phenotype 
generation (Okamura, et al, 1998) and it may be, therefore, that other cytokines 
such as IL-18 have a role in activation of CTL. This may explain why antagonism
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of IL-12 alone is insufficient to inhibit CTL activity. In the current study, 
however, CTL activity was assessed in preparations of cells from the spleens of 
treated animals. Thus only one compartment of lymphoid tissue was assessed. It 
may be that CTL activity in draining lymph nodes, for example, was reduced by 
pre-treatment with anti-IL-12 antibody and this would be an interesting issue to 
address in the future.
Interestingly, while treatment with anti-IL-12 antibody did not reduce CTL 
activity, it did have a significant effect on non-specific cytotoxicity. Cells removed 
from animals pre-treated with both anti-IL-12 antibody and donor cells showed 
considerably less NK cell cytotoxic activity in vitro compared to cells from 
animals pre-treated with donor cells alone. The possibility that such reduced NK 
cell activity may be important in the prolongation of allograft survival by 
preventing the rapid destruction of injected donor cells was addressed.
Various authors have described how persistence of donor antigen within 
the host leads to hyporesponsiveness when the host is rechallenged by a graft 
(Bushell et al, 1995, Sheng-Tanner and Miller, 1994). NK cells are thought to be 
the cell type responsible for the rapid elimination of fully allogeneic cells injected 
intravenously, and probably also for the removal of semi-allogeneic cells (Sheng- 
Tamier and Miller, 1992). Thus, by inhibiting NK cell cytotoxicity, anti-IL-12 
antibody may permit increased survival of injected donor splenocytes, allowing 
microchimerism to develop within the host and so induce hyporesponsiveness to a 
subsequent skin graft.
Against this, however, is the finding that, in this experimental model, pre­
treatment with anti-IL-12 antibody did not increase survival of injected donor
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strain spleen cells in host lymphoid tissue when assessed by FACS analysis. These 
findings differ from those of Sheng-Tanner and Miller (1994), who found that 
BDFi cells, previously labelled with FITC and then injected intravenously into 
C57B1/6 mice, could be detected in host lymphoid tissue 3 days after injection. 
They concluded that persistence of these injected cells leads to a state of 
microchimerism and this is necessary for the prolongation of graft survival. In 
their experiments, as already discussed, injection of BDFi cells alone led to 
prolonged skin graft survival in C57B1/6 recipients. The finding in this work that 
BDFi cells were not present at 3 days after injection either in unmodified mice or 
in those pre-treated with anti-IL-12 antibody is obviously at variance with their 
findings. However, in the work presented here, as no prolongation of graft 
survival was found in the group treated with donor cells alone, but was seen in the 
group treated with both donor cells and anti-IL-12 antibody, this indicates either 
that a state of microchimerism is not important for allograft survival in this model, 
or else detection of donor cells by FACS analysis labelling cells after injection 
into this host is not effective. Differences in the injected cell population in Sheng- 
Tanner’s work, or differences in the methods used to detect persisting donor cells 
may, therefore, be of relevance. It would be of interest, therefore, to investigate 
this in the future by labelling donor cells with FITC prior to injection and then 
attempting to quantify persistence of donor cells.
In the work presented here, pre-treatment with anti-IL-12 antibody prior to 
donor cell treatment did not produce a detectable state of microchimerism within 
host animals. This finding is supported by the work of Woods’ group (Bushell et 
al, 1995) who found that, in their model of prolonged heart graft survival in mice
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treated with donor-specific transfusion plus anti-CD4 antibody, the generation of a 
state of microchimerism is not required for tolerance induction. Tolerance could 
be achieved by injecting irradiated donor cells with anti-CD4 antibody, indicating 
that persistence of viable cells is not required in that model.
Another possibility is that NK cells, via production of IFN-y in response to 
IL-12, are directly responsible for the polarisation of T-helper cells, with IFN-y 
and IL-12 inducing a Thl phenotype. Romagnani (1992) proposed that the innate 
immune response, including NK cell activity, determines the subsequent specific 
immune response of CD4"  ^T cells. Antigenic challenge of undifferentiated CD4^ T 
cells in association with activation of NK cells produces a cascade of events i
resulting in the development of a Thl response or the deviation of an expected 
Th2 response to a ThO or Thl phenotype. Manetti et al (1993) showed that the 
ability of IL-12 to promote the development and differentiation of Thl-type cells 
in vitro was, at least in part, due to its stimulatory effects on NK cells. They 
proposed that the generation of Thl responses was due to the components of the
innate immune response providing optimum conditions for the development of 
Thl cells. Thus, in this model, allograft survival may be a consequence of anti-IL-
12 antibody’s inhibitory action on NK cell activation, which, in turn, fails to create 
the optimum conditions for Thl cell generation and, instead, leads to Th2 cell 
generation. The presence of donor antigen at this time may mean that when the 
host immune response is re-exposed to that antigen in the form of a skin graft, a 
Th2 response is generated. |
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5.7 Summary of Results of C hapter 5
1. Spleen cells prepared from skin graft recipients pre-treated with anti-IL- 
12 antibody and donor spleen cell injection show similar levels of CTL activity as 
cells from unmodified graft recipients when assessed in chi’omium release 
cytotoxicity assays.
2. NK cell activity is, however, reduced in cultures of spleen cells from 
mice pre-treated witli anti-IL-12 antibody compared to those from unmodified 
animals.
3. Pre-treatment of mice with anti-IL-12 antibody is not associated with increased 
survival of injected donor strain spleen cells within the host, indicating that such 
treatment does not encourage a state of microchimerism to develop.
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spleen (%) lymph node (%)
donor cells 1.8 +/-0.3 0.9 +/-0.1
donor cells + goat IgG 1.9 +/-0.2 0.9 +/-0.2
donor cells + aIL-12 1.4 +A0.4 0.7 +/-0.1
Table 5.1 Persistence of injected BDFi cells at 24 hours in the spleen and 
lymph nodes of recipient animals. 5 x 10  ^ BDFi spleen cells were injected iv 
into C57B1/6 mice and cells harvested from the spleens and lymph nodes of 
recipient animals 24 hours later. The percentage of injected donor cells +/- 1 
standard deviation, as detected by FACS analysis, is shown for animals injected 
with spleen cells alone (donor cells), animals pre-treated with 0.5 mg goat IgG 
injected ip 24 hours prior to BDFi spleen cell injection (donor cells + goat IgG) 
and animals pre-treated with 0.5 mg anti-IL-12 antibody injected ip 24 hours prior 
to BDFi spleen cell injection (donor cells + aIL-12). Percentages are the means of 
3 experiments.
spleen (%) lymph node (%)
donor cells 1.1 +/-0.1 4.2 +/-2
donor cells + goat IgG 0.7 +/-0.1 1.4 +/-0.3
donor cells + aIL-12 0.6 +/.0.1 1.7 +/-0.4
Table 5.2 Persistence of injected BDFi cells at 72 hours in the spleen and 
lymph nodes of recipient animals. 5 x 1 0 ^  BDFi spleen cells were injected iv 
into C57B1/6 animals in each of the groups as above. Spleens and lymph nodes 
were harvested at 72 hours after donor cell injection and the percentages of donor 
cells detected are shown.
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Effector : Target cell ratio
Figures 5.1 and 5.2 Percentage cytotoxicity 7 days after grafting.
Spleen cells were removed from C57B1/6 mice which had received BDFi skin 
grafts 7 days earlier and used in cliromium release cytotoxicity assays with either 
DBA/2 conA blasts or P815 cells as targets. Cells were taken from unmodified graft 
recipients (BDFi graft), animals which had been pre-treated with 5 x 1 0 ?  BDFi 
donor cells iv. 7 days prior to grafting (BDFi graft + donor cells) and animals 
pre-treated with both donor cells and 0.5 mg anti-IL-12 antibody on days -8, -5,
-2 and 1 (BDFi graft + donor cells + aIL-12).
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Figures 5.3 and 5.4 Percentage cytotoxicity 10 days after grafting.
Cells were removed from grafted C57B1/6 mice in the same treatment groups 
as in Figures 5.1 and 5.2 and cytotoxicity assessed against either DBA/2 conA 
blasts or P815 target cells in a cliromium release assay.
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Figure 5.5 NK cell activity in vitro. Spleen cells were removed from C57B1/6 
mice and tested in a cln'omium release assay against YAC-1 target cells. Cells 
were removed from naïve animals (naïve), animals which had received 5 x 1 0  
BDFi cells iv. 24 hours previously (donor cells) and animals which had received 
the same donor cell pre-treatment plus 0.5 mg anti-IL-12 antibody ip. 24 hours 
prior to that (donor cells + aIL-12). Results are the calculated percentage 
cytotoxicity for each effector cell concentration +/- 1 standard deviation from 1 
experiment which was representative of 3.
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CHAPTER 6
FINAL DISCUSSION
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Interleukin-12 is a key immunoregulatory cytokine, playing a central role 
in the differentiation of T helper cells. It stimulates both NK cells and T cells to 
produce IFN-y, amplifying the Thl response, and induces the differentiation of 
ThO into Thl cells. Allograft rejection is usually associated with an up-regulated 
Thl response, and prolonged graft survival associated with a reduced Thl 
response and an up-regulated Th2 response. The aim of this work was, therefore, 
to investigate whether, by neutralising endogenous IL-12 around the time of skin 
grafting, allograft survival would be prolonged and whether this would be 
associated with an up-regulated Th2 response.
Pre-treatment with a polyclonal anti-IL-12 antibody prior to skin grafting 
did not prolong allograft survival in a semi-allogeneic murine model with BDF i 
tail skin grafted onto either C57B1/6 or DBA/2 recipient mice. Intravenous 
injection of donor strain spleen cells 7 days prior to grafting also failed to prolong 
graft survival. However, when these two therapies were combined, namely pre­
treatment with both anti-IL-12 antibody plus donor strain spleen cell injection, 
allograft survival was significantly prolonged. Interestingly, the timing of each 
treatment was significant, because spleen cell injection just prior to skin grafting 
in mice which had been pre-treated with anti-IL-12 antibody as before failed to 
prolong allograft survival. The combination of donor cell injection plus anti-IL-12 
antibody pre-treatment was not able, however, to prolong skin graft survival in a 
fully allogeneic mismatch, where C57B1/6 skin was grafted onto DBA/2 recipients 
or vice versa.
Unmodified skin graft rejection was characterised by an up-regulated Thl 
response when cells prepared from the spleens of grafted animals were re­
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stimulated in vitro with donor antigen. Pre-treatment of graft recipients with anti- 
IL-12 antibody alone reduced this Thl response, with less IFN-y and IL-2 being 
produced by spleen cells in vitro, but did not abolish it. Antagonism of 
endogenous IL-12 alone also led to a weak Th2 response when cells were re- 
stimulated in vitro. This indicates that antagonism of IL-12 alone is not sufficient 
to prevent the generation of a Thl response. This finding supports recent evidence 
that another cytokine, Interferon-y-Inducing Factor, or IL-18, is capable of 
inducing IFN-y production independently of IL-12 and so generating a Thl 
response.
When cells from grafted animals pre-treated with a combination of donor 
spleen cells injected intravenously and anti-IL-12 antibody were re-stimulated in 
vitro, the Thl response was markedly down regulated and a Th2 response was 
generated. This treatment regime was associated with prolonged allograft survival. 
In this model, while the generation of Th2 response was associated with prolonged 
allograft survival, the levels of the Th2 cytokines produced in vitro were still low. 
Thus, while a Th2 response was detectable, it may not be the actual cause of the 
prolonged graft survival. Interestingly, pre-treatment with donor spleen cells alone 
was associated with a down-regulated Thl response when cells from treated 
animals were re-stimulated in vitro, but no increase in the Th2 response. Despite 
these changes, no increase in skin graft sm'vival was seen in this group. This 
would indicate that allograft rejection can occur in the absence of a Thl response 
and rejection takes place at the same speed as with a normal Thl response. 
Flowever, in this group, there was no up-regulation of the Th2 response and it may 
be that this is the significant factor for prolonging allograft survival.
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Pre-treatment with anti-IL-12 antibody after donor cell injection did not 
affect CTL activity as assessed by an in vitro chromium-release cytotoxicity assay, 
indicating that the prolongation of skin graft survival in this group was not 
attributable to the inliibition of CTL activity. Similar findings have been reported 
in a cardiac allograft model, where antagonism of endogenous IL-12 alone did not 
prolong graft survival, and inhibition o f IL-12 did not significantly affect in vivo 
CTL responses (Piccotti et a l , 1997, b).
Pre-treatment with anti-IL-12 antibody did, however, reduce NK cell 
activity compared to unmodified controls. This result would be anticipated as IL- 
12 is known to act directly on NK cells, stimulating them to produce IFN-y. The 
significance of this finding in the context of allograft rejection is, however, less 
clear. Despite this reduction in NK cell activity, a state of microchimerism in 
animals pre-treated with both donor spleen cells and anti-IL-12 antibody, where 
donor strain cells survive indefinitely within the graft recipient, could not be 
demonstrated. Thus the mechanism for prolonged graft survival in this model 
could not be demonstrated to be due to prolonged survival of injected donor cells 
due to a reduction in NK cell destruction of such cells. This finding, however, 
merits further investigation.
Prolonged skin graft survival was associated with a down-regulated Thl 
response and an up-regulated Th2 response. This may be due to the effects of anti- 
IL-12 antibody and injected donor cells directly on Th cells, or it may also be due 
to effects on NK cells. By inhibiting NK cell function, the optimal environment 
for the differentiation of ThO cells into Thl cells may have been prevented, and a 
Th2 response generated instead.
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These cytokine responses were, however, seen in single cell suspensions 
from the spleens of grafted animals. Obviously, such in vitro findings may not 
accurately reflect the local cytokine environment within the rejecting graft. In 
addition, in many of the experiments, only spleen cells were assessed and it may 
be that differences in responses could have been detected if cells from different 
lymphoid compartments such as draining lymph nodes had been assessed. 
However, spleen cell preparations did show consistent and reproducible 
differences between the treatment groups.
This work has demonstrated that the Thl/Th2 paradigm does have some 
relevance in allograft rejection. Antagonism of endogenous IL-12, with its central 
role in the differentiation of Th cells, can have some influence on the immune 
response to a graft but, on its own, is not sufficient to prolong allograft survival. 
However, when inhibition of IL-12 is combined with some other 
immunomodulating treatment, in this case the injection of donor strain spleen 
cells, prior to grafting, a strong Tli2 response can be induced and allograft survival 
prolonged.
Prolonged graft survival in a skin graft model is often difficult to achieve 
and therefore these results indicate that the prolongation in allograft survival seen 
in this model is significant. It may be that by using a similar treatment protocol in 
a less demanding model, such as a vascularised heart graft, further increases in 
survival may be achieved. In addition, as evidence accumulates on the role of 
other cytokines such as IL-18 on Thl cell generation, it would be interesting to 
attempt to neutralise the effects of both IL-12 and IL-18 in this model.
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This work has demonstrated that, by effecting a shift from a Thl to a Tli2 
response, allograft survival can be prolonged and this may have some implications 
for clinical transplantation. Treatment of transplant recipients with mAh has been 
used before and so antagonism of immunoregulatory cytokines at the time of 
transplantation by such means may prove to be beneficial. Clinical trials using 
recombinant IL-12 in a variety of conditions such as AIDS have started (Gately et 
al, 1998) but, as yet, an IL-12 antagonist suitable for clinical testing has not yet 
been identified. Were such an antagonist found it may prove to have a role in the 
prevention of transplant rejection.
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